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Executive Summary
In recent decades, concern has grown over the presence of
pharmaceutical and personal care products (PPCPs) in water. This
concern stems from the possibility that the presence of PPCPs in
water supplies may pose a threat to both human and environmental
health. Such threats may be both direct (e.g., exposure to
endocrine disrupting compounds) and indirect (e.g., emergence of
antibiotic resistant bacteria). The water treatment and wastewater
treatment community has been especially concerned over PPCPs
because of PPCPs ubiquitous nature and their ability to persist or
only partially degrade in water and during wastewater treatment.
Studies done over the past several decades have indicated that
wastewater contaminants including antibiotics, other prescription
drugs, non-prescription drugs, steroids, reproductive hormones,
and personal care products have been found in both surface water
and ground water in the United States.
Sources of PPCPs include human & animal feces and urine,
hospital/medical wastes, wastes from industrial and agricultural
processes, pharmaceuticals and personal care products that are
disposed of inappropriately, urban runoff, and leachate from
landfills. These contaminants are rarely treated or removed in
the wastewater treatment process and typically remain in waters
discharged from wastewater treatment plants into receiving streams
and lakes, as well as in solid and liquid wastes applied to lands
designated as application sites.
Various common law remedies, such as trespass, nuisance,
negligence, and strict liability, may be relevant to concerns over
PPCPs in water supplies. However, these remedies rely on success
in litigation. Litigation is often expensive, time consuming, and
very case specific. Additionally, success in litigation requires
plaintiffs to prove causation – which manufacturer produced the
PPCP involved in the suit, and which PPCPs resulted in the harm
alleged in the suit – hurdles that may be difficult to overcome.

(ESA). States and tribes have enacted similar legislation. While
these strategies may prove to be important, their implementation
can be expensive and politically unpopular.
A more effective route for responding to PPCPs in drinking
water supplies may be to focus on alternative strategies that
focus on removing PPCPs from the source. These alternative
strategies include designing drugs and personal care products
that minimize the human and animal excretion of wastes, which
would then minimize the volume of PPCPs that enter the water
system. Changing the delivery mechanisms may also be successful
in addressing PPCPs in water systems. This strategy relies on
better informing doctors and patients about the effects of PPCPs
on the environment, and educating doctors and other professionals
on how to individualize or tailor doses to the individual user
rather than prescribing the manufacturers’ recommended dose.
Informing users on how to dispose of unused drugs and personal
care products and producing a variety of package sizes to reduce
the amount of unused drugs could also be an essential PPCP
reducing mechanism.
In addition, encouraging states or manufacturers of
pharmaceuticals and personal care products to develop take-back
programs could also lead to the reduction of PPCPs in the water
supplies. Unfortunately, institutional and financial barriers may
make implementing of many of these programs difficult. For
take-back programs to be successful, these institutional barriers
need to be revised. Nutrition and health maintenance programs
that reduce illness and the need for PPCPs, as well as the use of
alternative products that do not contain PPCPs, such as probiotics,
also could reduce the amount of PPCPs entering the water supply.
This alternative, however, could also be costly to the patient.
The issue of PPCPs in water supplies is a complex problem
that will require more than one simple solution. It will require
reducing the source of PPCPs and monitoring and regulating the
PPCPs that enter the water supply. New monitoring, detection,
and analysis methods are needed. New drinking water treatment
processes will need to be developed. Regulatory and statutory
approaches need to be tailored to reducing the amount of PPCPs
in water supplies. The alternative strategies discussed here will be
needed to protect human and environmental health.

An alternative to common law remedies may be found under
federal, state, and tribal laws and regulations where a number of
agencies and statutes may be relevant. Federal agencies that have
the potential to be involved in various aspects of the management
of PPCPs include the Environmental Protection Agency (EPA),
the Food and Drug Administration (FDA), the U.S. Department
of Agriculture (USDA), the U.S. Geological Survey (USGS),
and the Centers for Disease Control and Prevention (CDC). In
addition, numerous units of state, tribal, and local governments
may be involved in implementing environmental programs that are
relevant to the management of PPCPs. Existing federal statutory
regimes that may be relevant to PPCPs include: Clean Water Act;
Safe Drinking Water Act; Resource Conservation and Recovery
Act; Toxic Substance Control Act; and Endangered Species Act
ii

A. Introduction:
compounds (EDCs) have received growing attention from the
water treatment and wastewater treatment community because of
the ability of PPCPs to persist or only partially degrade in water
and during wastewater treatment.4

In the nearly forty years since the adoption of the Federal
Water Pollution Control Act Amendments in 19721 and
the Safe Drinking Water Act in 1974, 2 the United States
has seen dramatic improvement in the quality of both
surface and drinking water. Despite these improvements,
serious problems and questions remain.

Several federal agencies, including the Environmental
Protection Agency (EPA), the Food and Drug Administration
(FDA), the U.S. Department of Agriculture (USDA), the U.S.
Geological Survey (USGS), and the Centers for Disease Control
and Prevention (CDC), have the potential to be involved in various
aspects of the management of PPCPs. In addition to these federal
agencies, numerous units of state, tribal, and local governments
are (or could be) involved in implementing federal, state, and tribal
environmental programs that are relevant to the management of
PPCPs. Industry stakeholders also play significant roles, both
directly and indirectly, in the management of PPCPs.

Chemicals occur in the environment through a wide variety
of natural processes and human actions. The various federal and
state programs implementing the Clean Water Act, the Safe
Drinking Water Act and other environmental laws regulate only
a small portion of these chemicals. Although the number of
regulated chemicals is very small when compared to the universe of
chemicals in the environment, an implicit assumption underlying
this regulatory approach is that “these selective lists of chemicals
are responsible for the most significant share of risk with respect to
environmental or economic impairment or to human health.”3

PPCPs are an extremely diverse group of chemicals used
in human health care, cosmetic care, veterinary medicine,
and agriculture. They also are ubiquitous pollutants, entering
the environment worldwide due to widely dispersed usage by

In recent years, this assumption has been challenged.
Chemicals from a wide variety of pharmaceutical and personal
care products (PPCPs), their byproducts and endocrine disrupting

Pub. L. No. 92-500, 86 Stat. 816 (1972) (codified as amended at 33 U.S.C. § 1251 et seq. (2006)) (with subsequent amendments, now
known as the Clean Water Act).
1

2

Safe Drinking Water Act, Public Law No. 93-523, 88 Statutes at Large 1661.

Christian G. Daughton, Non-Regulated Contaminants Emerging Research, Existing and Future Pollutants in Water Supplies: Old
Pollutants, New Concerns - New Pollutants, Unknown Issues. Paper presented at the Presented at National Academies, Institute of
3

Medicine: Roundtable on Environmental Health Science, Research, and Medicine (EHSRT) (Oct. 16, 2003).
For the purposes of this report, the term “PPCPs” includes a diverse group of chemicals that include pharmaceutical, such as prescription
and over-the-counter human drugs, veterinary drugs, and diagnostic agents, and personal care products, including fragrances, lotions,
cosmetics, and nutritional supplements. PPCPs also comprise the various byproducts of these substances as well as related endocrine
disrupting compounds (EDCs). Concern regarding the presence of such compounds in water supplies was expressed by Masters:
4

[These] are compounds that interfere with natural production, release, transport, metabolism, binding, action, or elimination
of hormones in the body. We know that the normal functions of all organ systems are regulated by endocrine factors. Small
disturbances in endocrine function, especially during certain stages of the life cycle, can lead to profound and lasting effects.
There is evidence that specific populations of invertebrate, fish, avian, reptilian, and mammalian species have been, or currently
are being, adversely affected by exposure to environmental contaminants that effect the endocrine systems. … The major groups
of animals potentially at risk include fish, birds, reptiles, marine mammals, and invertebrates.
Robert W. Masters, Pharmaceuticals and Endocrine Disruptors in Rivers and On Tap, Water Resources Update, no. 120, 1, 1 (2001)
(citing Gerald Ankley et al., Office of Research and Development, Environmental Protection Agency, Research Plan for Endocrine
Disruptors. (1998)). See also K. Xia et al., Occurrence, Distribution, and Fate of 4-Nonylphenol in Kansas Domestic Wastewater Treatment
Plants, 120 WATER RESOURCES UPDATE 41 (2001).
Christian G. Daughton, Chapter 33: PPCPs in the Environment: Future Research – Beginning with the End Always in Mind, in
Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks 463 (Klaus Kümmerer ed., 2d ed. Springer 2004).
5
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individuals and in both industry and agriculture.5 Recent reports in
popular media regarding pharmaceuticals in drinking water have
contributed to increasing public awareness of and concern about
this issue.6

Project 2 focused on primary research to improve the
understanding of the presence and fate of mixtures of
micropollutants in the environment. This research, which was based
on field studies conducted on discharges from a wastewater treatment
facility in West Texas, forms the basis for the case study noted below.

In 2006, the Center for Water Law & Policy at Texas
Tech University (the “Center”) was awarded funding by the
Environmental Protection Agency to conduct a study related to
micropollutants (including PPCPs) in the natural environment.
This study was divided into three specific projects.

Project 3 focused on an analysis of alternative strategies for
addressing the presence and effects of PPCPs in water supplies.
Statutory and regulatory approaches that are (or could be) utilized
to prevent PPCPs from entering the aquatic environment in
concentrations that would exceed concentrations determined to be
appropriate for protection of human health and the environment
were identified and evaluated.7 Potential alternative strategies
were also identified and evaluated. Project 3 addressed three basic
questions: First, can existing statutory and regulatory authorities
be utilized to collect information about and/or effectively manage
PPCPs entering the environment? Second, are there other
alternative strategies that should be considered? Third, what are
the relative strengths and weaknesses of the existing authorities
and alternative strategies? The results of Project 3 as well as
answers to these three questions are contained herein.

Project 1 focused on the development of a PPCP database
containing documents, reports, publications, and other material
related to PPCPs. While information in the database was designed
for use in Project 3 (discussed below), the information was also
intended to be made available to those interested in understanding
water law and policy issues, including researchers, decision-makers
in the public and private sectors, stakeholders, interest groups,
and the general public. This latter objective was achieved by the
creation of the Micropollutants Clearinghouse
(http://www.micropollutants.org).

For example, in 2008, the Associated Press released a series of investigative reports entitled An AP Investigation: Pharmaceuticals
found in Drinking Water. These reports, which were distributed by both print and electronic media worldwide, included: Jeff Donn,
PharmaWater – NYC Water: Drug Traces Turn Up in Source Waters for Nation’s Biggest City ; Jeff Donn, PharmaWater – Philadelphia
Drugs: Tests of Philadelphia’s Drinking Water Reveal 56 Drugs ; Jeff Donn, PharmaWater – Research: Research Shows Pharmaceuticals in
Water Could Impact Human Cells ; Jeff Donn, House Panel Pressed to Consider More Tracking of Pharmaceuticals, Contaminants in US
Waters; Jeff Donn, Medical Facilities Making Uncontrolled Releases of Controlled Drugs into Water ; Jeff Donn, Philadelphia City Council
Wants Local and Federal Action to Curb Drugs in Drinking Water Jeff Donn, Philadelphia Water Officials to Address Worries over Drugs in
Water and Corrected Data ; Jeff Donn, Martha Mendoza & Justin Pritchard, Pharmawater I: Pharmaceuticals Found in Drinking Water,
Affecting Wildlife and Maybe Humans ; Jeff Donn, Martha Mendoza & Justin Pritchard, Pharmawater II: Fish, Wildlife Affected by Drug
Contamination in Water ; Jeff Donn, Martha Mendoza & Justin Pritchard, Pharmawater III: No Standards to Handle Pharmaceuticals in
Water ; Jeff Donn, Martha Mendoza & Justin Pritchard, AP Impact: Health Care Industry Sends Tons of Drugs into Nation’s Wastewater
System ; Jeff Donn, Martha Mendoza & Justin Pritchard, AP Investigation: Scant Advice on Disposal of Meds ; Tom Hester, Jr., NJ
Lawmakers Told Effects of Drugs in Water Unknown ; Steve LeBlanc, Mass. Officials Detail Steps to Keep Pharmaceuticals from Water
Supply, Call for Federal Help ; Colleen Long, NYC Leaders Say City Must Test Drinking Water, Responding to AP Report on Drugs ;
Martha Mendoza, PharmaWater-Secrecy: Water Providers, Researchers Rarely Release Full Test Results ; Martha Mendoza, AP Enterprise:
Recent Tests Detect Pharmaceuticals in Drinking Water of 46 Million Americans ; Martha Mendoza, Communities Prevent Pharmaceutical
Contamination with Drug Takeback Programs ; Martha Mendoza, Ill. Orders Water Testing in Reax to AP Series; Providers Elsewhere
Assure Supplies are OK; Martha Mendoza, On Eve of Hearings, White House Documents Show Feds Failing to Take Action on Drugs
in Water ; Martha Mendoza, Scientists, Environmentalists, Utilities Agree: More Testing Needed on Drugs in Drinking Water ; Martha
Mendoza, Senators Rip EPA Over Lack of Knowledge on Drugs in Water ; Martha Mendoza, Texas Town Releases Name of Drug Found
in Water; Mayor Cited Terrorism as Reason for Secrecy ; Justin Pritchard, PharmaWater – Bottled Water: Bottled Water Industry Faces Same
Federal Standards for Pharmaceuticals as Tap Water ; Justin Pritchard, PharmaWater – Treatments: Water Cleaning Technologies Present
Challenges ; Carolyn Thompson, EPA Urges Great Lakes Residents Not to Flush Old Meds.
6

The alternatives analysis contained in Project 3 was not designed to determine whether human health and environmental hazards presented
by PPCPs and their byproducts warrant specific regulatory activities. Instead, Project 3 was intended to evaluate alternative strategies that
could be utilized should scientific research determine that PPCPs or their byproducts are hazardous to human health or the environment.
7
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A.1. Methodology

A.2. Organization of the Report

Preparation of this report relied on both the outputs of Projects
1 and 2 and on the collective expertise of the authors. As noted
above, the output of Project 1 (the Micropollutants Clearinghouse)
contained an extended collection of materials relating to PPCPs
in water supplies. The following section summarizes the current
scientific research. Both this summary and Section IV regarding
alternative strategies were prepared after the authors had
reviewed a large number of articles and reports contained in the

The following section provides a brief summary of current
scientific research regarding sources of PPCPs in water supplies.
Processes or mechanisms by which PPCPs get into water supplies
are described. Both short- and long-term impacts on human and
environmental health resulting from the presence of PPCPs in
water supplies are reviewed.
Section III describes current legal mechanisms by which water
supplies are protected, both directly and indirectly. The requirements
of the Clean Water Act and the Safe Drinking Water Act are
reviewed. The management of hazardous substances and wastes,
as mandated by the Resource Conservation and Recovery Act, is
reviewed as is the regulation of toxic substances under the Toxic
Substances Control Act. Of particular relevance to the aquatic
environment is the Endangered Species Act, which is also reviewed.

Clearinghouse.
To ensure comprehensiveness, and as a quality control measure,
the authors also undertook an independent review of the literature.
This review utilized a variety of online data retrieval systems.
The results of this independent review were then compared to
the contents of the Clearinghouse. Any items not already in the
Clearinghouse were added following this review.8

Potential alternative strategies leading to the minimization or
elimination of PPCPs in water supplies are discussed in Section
IV. This discussion, which addresses the reduction or elimination
of anthropogenic sources of PPCPs, as well as the regulation and
management of such sources, sets the stage for the aforementioned
case study contained in Section V. As noted above, this case study
is based on Project 2 results.

Project 2 provided the information contained in the case
study discussed below. This research, which focused on the
presence of PPCPs in soil and groundwater in West Texas, was
initiated by researchers at Texas Tech University, specifically
Dr. Todd A. Anderson, Dr. Deborah L. Carr, Dr. Adcharee
Karnjanapiboonwong, Dr. Jonathan D. Maul, Dr. Audra N.
Morse, and Dr. John C. Zak.9 Meetings were held with one or
more of these researchers during the course of this project. Copies
of research presentations and drafts of final reports were provided
to the authors. The cooperation and assistance of Dr. Anderson,
Dr. Carr, Dr. Karnjanapiboonwong, Dr. Maul, Dr. Morse, and Dr.
Zak are both acknowledged and very much appreciated.

Strengths and weaknesses of the statutory, regulatory, and
alternative strategies are discussed in Section VI. Conclusions
are presented in Section VII. Section VIII contains the Project 3
bibliography.

The legal review contained in Section IV and the analysis of
the strengths and weaknesses of a variety of statutory and regulatory
alternatives contained in Section VI are based primarily on the
expertise of the authors, both of whom have taught environmental,
natural resources, and water law for many years. This expertise
was supplemented by additional legal research regarding recent
initiatives unique to the issue of PPCPs in water supplies.10

B. Summary of the Scientific Research:
Concern over the presence of PPCPs in water supplies has
increased significantly since 1965 when researchers at Harvard
University first determined that effluent from wastewater treatment
plants contained both natural and synthetic estrogens.11 By the

The comprehensiveness of the research upon which the Clearinghouse was based is revealed by the fact that relatively few new references
were added following the authors’ independent review of the literature.
8

Dr. Anderson, Dr. Carr, Dr. Karnjanapiboonwong and Dr. Maul are with the Institute of Environmental and Human Health,
Department of Environmental Toxicology. Dr. Morse is with the Department of Civil and Environmental Engineering. Dr. Zak is with
the Department of Biological Sciences.
9

The authors would like to express their appreciation to Mr. Christopher R. Jackson, Class of 2011, Texas Tech University School of Law,
and Ms. Elizabeth Miller, Class of 2011, Texas Wesleyan University School of Law, for their invaluable assistance in the preparation of this
portion of the report.
10

Benjamin D. Stanford et al.,.Estrogenic Activity of US drinking waters: A relative exposure comparison, 102 Journal of the American
Water Works Association 55, 55 (2010) (citing Elisabeth Stumm-Zollinger & Gordon M. Fair, Biodegradation of Steroid Hormones, 37
Journal of the Water Pollution Control Federation 1506 (1965)).
11
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into which wastewater had been discharged.15 In large measure,
the growing concern over the presence of PPCPs in water supplies
has been based on an increasing number of occurrence studies
that have identified specific PPCPs in drinking water.16 While it
is beyond the scope of the present study to review each of these
studies, certain studies should be noted.

1970s, the subject was being studied in both the United States12
and in Europe.13
However, as noted by Stanford, et al., after these initial studies
“only sparse attention was paid to hormones and pharmaceuticals
in the environment until reproductive effects in fish were shown
to be directly influenced by estrogens in wastewater outfalls.”14
By the early 1990s, researchers in Germany and Switzerland had
identified multiple PPCPs in both wastewater and surface waters

Id. at 55 (citing A.W. Garrison et al., GC/MS Analysis of Organic Compounds in Domestic Wastewaters, in First Chemical congress
of the North American Continent 517 (1975)).

12

Lisa J. Schulman et al., A Human Health Risk Assessment of Pharmaceuticals in the Aquatic Environment, 8 Human & Ecological Risk
Assessment 657, 658 (2002).
13

Stanford et al., supra note 11, at 55-56 (citing Shane A. Snyder et al., Identification and Quantification of Estrogen Receptor Agonists in
Wastewater Effluents, 35 Environmental Science & Technology 3620 (2001); C. Desbrow et al., Identification of Estrogenic Chemicals
in STW Effluent. 1. Chemical Fractionation and in Vitro Biological Screening, 32 Environmental Science & Technology 1549 (1998)).
14

David L. Sedlak, & Karen E. Pinkston, Factors Affecting the Concentrations of Pharmaceuticals Released to the Aquatic Environment,
120 Water Resources Update 56 (2001) (citing H.J. Stan et al., Occurrence of Clofibric Acid in the Aquatic System – Is the Use in
Human Medical Care the Source of the Contamination of Surface, Ground, and Drinking Water? 83 Vom Wasser 57 (1994); R. Hirsch
et al., Determination of Betablockers and ß-Sympathomimetrics in the Aquatic Environment, 87 Vom Wasser 263 (1996); H. Stan & T.
Heberer, Occurrence of Polar Organic Contaminants in Berlin Drinking Water, 86 Vom Wasser 19 (1996); Marcus Stumpf et al., Polar
Drug Residues in Sewage and Natural Waters in the State of Rio de Janeiro, Brazil, 225 The Science of the Total Environment 135
(1999); Hans-Rudolf Buser et al., Occurrence of the Pharmaceutical Drug Clofibric Acid and the Herbicide Mecoprop in Various Swiss Lakes
and in the North Sea, 32 Environmental Science & Technology 188 (1998); Hans-Rudolf Buser et al., Occurrence and Fate of the
Pharmaceutical Drug Diclofenac in Surface Waters: Rapid Photodegradation in a Lake, 32 Environmental Science & Technology 3449
(1998); Andreas Hartmann et al., Identification of fluoroquinolone antibiotics as the main source of umuC genotoxicity in native hospital
wastewater, 17 Environmental Toxicology and Chemistry 377 (1998); Thomas A. Ternes, Occurrence of Drugs in German Sewage
Treatment Plants and Rivers, 32 Water Research 3245 (1998); Hans-Rudolf Buser et al., Occurrence and Environmental Behavior
of the Chiral Pharmaceutical Drug Ibuprofen In Surface Waters and in Wastewater, 33 Environmental Science & Technology 2529
(1999); C. Hartig, Detection and Identification of Sulphonamide Drugs in Municipal Waste Water by Liquid Chromatography Coupled
with Electrospray Ionisation Tandem Mass Spectrometry, 854 Journal of Chromatography A 163 (1999); Roman Hirsch, Occurrence of
Antibiotics in the Aquatic Environment, 225 The Science of the Total Environment 109 (1999); Thomas A. Ternes & Roman Hirsch,
Occurrence and Behavior of X-ray Contrast Media in Sewage Facilities and the Aquatic Environment, 34 Environmental Science &
Technology 2741 (2000)). Schulman, et al., have noted that these studies “identified and measured a variety of human pharmaceuticals
including hormones, lipid regulators, pain killers, antibiotics, anticancer drugs, anti-epileptic drugs, and blood pressure drugs at a range of
concentrations, most below 1 μ/l.” Schulman et al., supra note 13, at 658.
15

However, as noted by the American Water Works Association Research Foundation (AwwaRF), “[i]f water utilities choose to (or
are compelled to) implement additional treatment measures for these compounds based solely on occurrence data, without regard to
toxicological significance, there is a risk of spending tremendous amounts of public funds for very little public health benefit.” Djanette
Khiari, Endocrine Disruptors, Pharmaceuticals, and Personal Care Products in Drinking Water: An Overview of AwwaRF Research to
Date, 17 Drinking Water Research 1, 6 (2007) (emphasis added). The AwwaRF has also noted:
16

If presence/absence becomes our litmus test for risk and subsequent actions, treatment technology will be increasingly, and
perhaps unnecessarily, costly and energy intensive. This is an especially important consideration due to the energy cost and
greenhouse gas emissions of advanced treatment.
American Water Works Association Research Foundation, Toxicological Relevance of EDCs and Pharmaceuticals in Drinking Water, at xix
(2008).
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Figure 1: Pharmaceuticals, Hormones, and Other
Organic Wastewater Contaminants in U.S. Streams21

In 1999-2000, the U.S. Geological Survey sampled surface
and groundwater throughout the United States.17 The study
focused on the presence in U.S. water supplies of 95 organic
wastewater contaminants including “antibiotics, other prescription
drugs, nonprescription drugs, steroids, reproductive hormones,
personal care products, products of oil use and combustion,
and other extensively used chemicals.”18 At least one of the 95
organic wastewater contaminants was found in 80% of stream
samples and in 93% of groundwater samples. As noted in the
study, the environmental presence of these compounds raises
concerns regarding potential consequences, including “abnormal
physiological processes and reproductive impairment, increased
incidences of cancer, the development of antibiotic-resistant
bacteria, and the potential increased toxicity of chemical
mixtures.”19 The results of the study are summarized below and
depicted in Figure 1.
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The most frequently detected chemicals (found in
more than half of the streams) were coprostanol
(fecal steroid), cholesterol (plant and animal steroid),
N-Ndiethyltoluamide (insect repellent), caffeine
(stimulant), triclosan (antimicrobial disinfectant),
tri (2-chloroethyl) phosphate (fire retardant), and
4-nonylphenol (nonionic detergent metabolite). Steroids,
nonprescription drugs, and insect repellent were the
chemical groups most frequently detected. Detergent
metabolites, steroids, and plasticizers generally were
measured at the highest concentrations.20
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Dana W. Kolpin et al., Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999-2000: A
National Reconnaissance, 35 Environmental Science & Technology 1202, (2002). The results of this study are summarized in
Kimberlee K. Barnes et al., Water-Quality Data for Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S.
Streams, 1999- 2000, U.S. Geological Survey, U.S. Dep’t of the Interior, No. Open-File Report 02-94 (2002), available at http://toxics.
17

usgs.gov/pubs/OFR-02-94/.
18

Kolpin et al., supra note 17, at 1203.

19

Id. at 1202 (citations omitted).

Herbert T. Buxton & Dana W. Kolpin, Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams,
United States Geological Society, Dep’t of the Interior, FS-027-02, at 2 (2002), available at http://toxics.usgs.gov/pubs/FS-027-02/.
20

21

Id.
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supplies “because antibiotic contaminants could perturb microbial
ecology, increase the proliferation of antibiotic-resistant pathogens,
and could pose threats to human health.”25 Masters summarized
this concern:

In 2001, Sedlak and Pinkston identified multiple prescription
drugs in wastewater.22 They estimated concentrations of such drugs in
wastewater, concluding that the concentrations ranged from “less than
1 ng/L to approximately 133,000 ng/L.”23 They went on to note:
The estimated concentrations are distributed over a
wide range with the majority of compounds estimated
to be present at concentrations between 100 and 1,000
ng/L. In general, the compounds expected to be present
at the highest concentrations consisted of analgesics
(e.g., acetominophen, ibuprofen) and antibiotics (e.g.,
amoxicillin, cephalexin). Because some of the analgesics
... also are available as over-the-counter products, their
concentrations in wastewater could be considerably
higher. Compounds estimated to be present at the
lowest concentrations tended to be potent drugs such as
hormones (e.g., medroxyprogresterone, equilin).24

One of the dominating concerns is the creation of
“Superbugs.” New strains of bacteria which are resistant
to antibiotics are common near major cities and in rural
areas and have been found in all 15 rivers from one study,
including the Mississippi, the Ohio, and the Colorado.
As bacteria is exposed to antibiotics they begin to adapt
in order to survive, not unlike some of the drug resistant
staph infections which have developed in hospitals. This
is a concern, but like so many of today’s environmental
issues, more research is needed.26
Also, in 2001, Huang, et al., noted the presence in water supplies
of antibiotics used in both human therapy27 and also in animal
husbandry, specifically beef, swine, and poultry production.28

Of particular concern is the presence of antibiotics in water
22

Sedlak & Pinkston, supra note 15.

23

Id. at 57.

24

Id. The pharmaceuticals that were identified suggest that a “larger suite of pharmaceuticals” may be present in water supplies. Id.

Ching-Hua Huang et al., Assessment of Potential Antibiotic Contaminants in Water and Preliminary Occurrence Analysis, 120 Water
Resources Update 30, 31 (2001), (citing Christian G. Daughton & Thomas A. Ternes, Pharmaceuticals and Personal Care Products in the
Environment: Agents of Subtle Change? 107 Environmental Health Perspectives 1 (1999)). Accord Elizabeth A. Frick et al., Presence
of Pharmaceuticals in Wastewater Effluent and Drinking Water, Metropolitan Atlanta, Georgia, July-September 1999, in Proceedings of
the Waer Resources Conference (Kathryn J. Hatcher ed.) (2001); Kelly A. Reynolds, Pharmaceuticals in Drinking Water Supplies,
45 Water Conditioning and Purification (2003), available at http://www.wcponline.com/column.cfm?T=T&ID=2199 [hereinafter
Reynolds, Pharmaceuticals in Drinking Water Supplies].
25

Masters, supra note 6, at 1. Furthermore, “higher levels of antibiotic resistant bacterial strains [have been detected] downstream from a
swine-feed facility, compared with upstream levels.” Rapid Public Health Policy Response Project, School of Public Health and Health
Services, The George Washington University, Pharmaceuticals are in the Drinking Water: What Does it Mean? 4 (2008) (citing
Amy R. Sapkota et al., Antibiotic-Resistant Enterococci and Fecal Indicators in Surface Water and Groundwater Impacted by a Concentrated
Swine Feeding Operation, 115 Environmental Health Perspectives 1040 (2007)). “Evidence suggests that exposure to subtherapeutic
doses of antibiotics has resulted in a detectable increase in antibiotic resistance in some bacteria.” Chad A. Kinney et al., Presence and
Distribution of Wastewater-Derived Pharmaceuticals in Soil Irrigated with Reclaimed Water, 25 Environmental Toxicology and
Chemistry 317, 323 (2006) (citing Rosamund J. Williams, & David L. Heymann, Containment of Antibiotic Resistance, 279 Science
1153 (1998); Wolfgang Witte, Medical Consequences of Antibiotic Use in Agriculture, 279 Science 996 (1998)). Accord Ken Carlson et al.,
Antibiotics in the Cache la Poudre River, Agronomy News, Dec. 2004, at 4.
26

“Antibiotics that are likely to be present in discharged municipal wastewater are primarily antibiotics used in human therapy.” Huang et
al., supra note 25, at 32.

27

As discussed in greater detail in Section VI, one of the challenges facing the use of statutory and regulatory mechanisms to address
PPCPs in water supplies is the fact that both the presence of PPCPs and their concentrations vary substantially. With regard to the use of
antibiotics in animal husbandry, this variability was noted by Huang, et al.:
28

[C]onsiderable differences in antibiotic usage exist among different food animal species (beef vs. swine vs. poultry). Therefore,
the types of antibiotic compounds that are likely to be found in surface water will strongly depend upon the types of livestock
operations within the watershed.

Id. at 33.
6

By 2002, it had been determined that “the amount of
pharmaceuticals and personal care products (PPCPs) released
into the environment each year is tantamount to the amount of

pesticides used each year.”29 The principal emerging PPCPs and
their uses were summarized by Ellis: 30

Table 1: Principal Emerging PPCP Compounds and Their Uses
Compound group/class
Pharmaceuticals
Veterinary & human
antibiotics
Analgesics & antiinflammatory drugs

Psychiatric drugs
Lipid regulators
Blockers
X-ray contrasts
Steroids & hormones
Personal care products
Fragrances

Compound
Trimethoprim, erytromycine, lincomycin,
sultamethaxole, chloramphenicol, amoxycillin
Ibuprofen, diclofenac, fenoprofen,
acetaminophen, naproxen, acetylsalicylic acid,
fluoxetine, ketoprofen, indometacine,
paracetamol
Diazepam, carbamazepine, primidone,
salbutamol
Clofibric acid, bezafibrate, fenofibric acid,
etofibrate, gemfibrozil
Metoprolol, propranolol, timolol, sotalol,
atenolol
Iopromide, iopamidol, diatrizoate
Estradiol, estrone, estriol, diethylstilbestrol
(DES)

Sun-screen agents
Insect repellents

Nitro, polycyclic and macrocyclic musks;
phthalates
Benzophenone, methylbenzylidene camphor
N,N- diethyltoluamide

Antiseptics

Triclosan, chlorophene

It is quite probable that the specific PPCPs identified in these
occurrence studies have been in drinking water supplies for years.31
PPCPs, which are manufactured in large quantities, have chemical
and physical properties that make it likely for them to end up in

29

hydrologic systems.32 Furthermore, certain PPCPs (e.g., antibiotics
and estrogens) may “persist in the environment either due to their
inability to biodegrade naturally or to their constant use keeping
them ever present.”33

Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25.

J.B. Ellis, Pharmaceutical and Personal Care Products (PPCPs) in Urban Receiving Waters, 144 Environmental Pollution 184, 185
(2006).
30

“As long as humans use prescription medicines and over-the-counter drugs, we will find trace amounts in wastewater, surface water,
groundwater and drinking water.” Global Water Research Coalition, GWRC Science Brief: Occurrence and Potential for Human
Health Impacts of Pharmaceuticals in the Water System 1 (2009). Accord Reynolds, Pharmaceuticals in Drinking Water Supplies,
supra note 25 (“it’s reasonable to assume that as long as pharmaceuticals have been in use, they, and their metabolites, have contributed to
the overall environmental contamination load”).
31

32

Frick et al., supra note 25, at 282.

33

Kelly A. Reynolds, Concern of Pharmaceuticals in Drinking Water, 50 Water Conditioning & Purification (2008), available at
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them to occur at very low levels, frequently at parts per trillion
(picogram) or parts per billion (nanogram) levels.

The increased detection of PPCPs may be the result of
dramatically improved testing equipment and procedures rather
than the result of any recent introduction of PPCPs into drinking
water supplies.34 Such new testing equipment and procedures
now allow for the detection of PPCPs at the nanogram, 35 or even
picogram,36 level. Until fairly recently, detection levels were at
the microgram level.37 Furthermore, as noted by Schulman, et
al., “detection limits are likely to decrease in the future, as more
sensitive analytical detection techniques become available.”38 In
essence, while the detection of PPCPs has increased in frequency
as testing equipment and procedures have improved, the actual
presence of PPCPs may not have changed significantly.39

B.1. Pathways
There are any number of pathways by which humans can be
exposed to PPCPs contained in water supplies. The most obvious
means is the consumption of water containing PPCPs. Other types
of water exposures (e.g., swimming, bathing, showering) may also
provide an exposure pathway.
Other exposure pathways are more indirect. Schulman, et al.,
note that certain PPCPs bioaccumulate in fish.40 The exposure

Most of the occurrence studies that have detected PPCPs found

http://www.wcponline.com/pdf/0804On_Tap.pdf [hereinafter Reynolds, Concern of Pharmaceuticals in Drinking Water]. In fact, the
presence of PPCPs in water supplies has been suggested as a possible indicator of human fecal contamination of those water supplies. Susan
T. Glassmeyer et al., Transport of Chemical and Microbial Compounds from Known Wastewater Discharges – Potential for Use as Indicators
of Human Fecal Contamination, 39 Environmental Science & Technology 5157 (2005). Accord Y. Carrie Guo & Stuart Krasner,

Occurrence of Primidone, Carbamazepine, Caffeine, and Precursors for N-Nitrosodimethylamine in Drinking Water Sources Impacted by
Wastewater, 45 Journal of the American Water Resources Association, 58, (2009).
“[A]s analytical techniques grew more sensitive over the years, many more pharmaceuticals have been detected in ambient water,
wastewater, and drinking water.” ToxServices LLC, Approaches to screening for risk from Pharmaceuticals in Drinking Water
and Prioritization for Further Evaluation 1 (2008). Accord American Water Works Association Research Foundation, supra
note 16, at xxii (“The reality is that nearly any chemical known to man could be detected in water using the most modern and sensitive
of analytical instrumentation”). See also Helen C. Poynton, & Chris D. Vulpe, Ecotoxicogenomics: Emerging Technologies for Emerging
Contaminants, 45 Journal of the American Water Resources Association 83 (2009) (advances in analytical techniques).
34

A nanogram (ng) is one billionth of a gram (1 x 10-9). The detection level of such tests is expressed as parts per billion (ppb). One ppb is
roughly equivalent to “one drop of water in an Olympic-sized swimming pool, or a single blade of grass in a football field[.]” Rapid Public
Health Policy Response Project, supra note 26, at 1.

35

A picogram (pg) is one trillionth of a gram (1 x 10-12). The detection level of such tests is expressed as parts per trillion (ppt). One ppt is
roughly equivalent to one “drop of water in one thousand pools” or one “blade of grass in one thousand football fields”. Rapid Public Health
Policy Response Project, supra note 26, at 1.

36

37

A microgram (μg) is one millionth of a gram (1 x 10-6). The detection level of such tests is expressed as parts per million (ppm).

Schulman et al., supra note 13, at 669. Accord American Water Works Association Research Foundation, supra note 16, at xix
(“considering the continued advancements in analytical technologies, today’s non-detectable contaminants will be tomorrow’s emerging
contaminants”).

38

39

As noted by the Global Water Research Coalition:
We hear more reports about the presence of pharmaceuticals in water mainly because of improvements of the analytical methods
of detection. What was not detectable in the past has become detectable today, even at very low concentrations.

Global Water Research Coalition, supra note 31, at 1.
40

Schulman et al., supra note 13, at 659.
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of both “major and minor exposure pathways” and concluding that
future risk assessments for PPCPs aggregate exposure assessments
across multiple pathways.42 This recognition was depicted
graphically by Ellis: 43

pathway, therefore, would be the human consumption of fish or
shellfish containing PPCPs.41
In reality, there is seldom a single exposure pathway. The
National Research Council recognized this, noting the existence

Figure 2: Sources and Pathways of PPCPs in the Urban Water Cycle
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Virginia L. Cunningham, Stephen P. Binks & Michael J. Olson, Human Health Risk Assessment from the Presence of Human
Pharmaceuticals in the Aquatic Environment, 53 Regulatory Toxicology & Pharmacology 39, 43 (2009).; Ellis, supra note 30, at
185 (citing Betty Bridges, Fragrance: emerging health and environmental concerns, 17 Flavour & Fragrance Journal 361 (2002)); Ake
Wennmalm & Bo Gunnarsson, Public Health Care Management of Water Pollution with Pharmaceuticals: Environmental Classification
and Analysis of Pharmaceutical Residues in Sewage Water, 39 Drug Information Journal 291, 296 (2005).
41

Committee on Toxicants and Pathogens in Biosolids Applied to Land, Board on Environmental Studies and Toxicology, Division on
Earth and Life Studies, National Research Council, Biosolids Applied to Land: Advancing Standards and Practices 13 (National
Academies Press 2002). Accord Kolpin et al., supra note 17, at 1202 (“there are a wide variety of transport pathways for many different
chemicals to energy and persist in environmental waters”).
42

Ellis, supra note 30, at 186. It should not be assumed that these are the only pathways by which exposure to PPCPs occurs. With regard
to estrogenicity, for example, the AwwaRF has noted:

43

[V]egetable juice had observed EEq [estradiol equivalent] values from 1.9 to 3.3 ng/L, while coffee ranged from 11 to 17
ng/L. Various brands of beer exhibited a broad range of results with EEq values ranging from 0.8 to 140 ng/L. The highest
estrogenicity was observed in soy-based food and beverage items such as soy sauce (28 – 510 ng/L), soy baby formula (1,500 –
1,900 ng/L) and soy milk (1,900 – 4,200 ng/L). ***
Considering that food items are not labeled, or often even tested, for emerging contaminants, it is difficult to argue that the choice
of exposure from food is any less involuntary than would be exposure from tap water. … [F]or the pharmaceuticals and potential
EDCs detected in water, exposure to people through water is expected to be small compared to exposures to potentially hazardous

9

B.2. Effects of PPCPs in Water

been documented in the literature. In addition, because
antibiotics are specifically designed to reduce bacterial
populations in animals, even low-level concentrations in the
environment could increase the rate at which pathogenic
bacteria develop resistance to these compounds.45

Though research is ongoing, it does not appear that short-term
exposure to specific PPCPs at the low levels noted above results in
adverse human health impacts.44 Unfortunately, the question of adverse
human or environmental health impacts resulting from PPCPs in
water is not as simple as the foregoing conclusion might suggest.

Furthermore, Reynolds has observed that “[t]rends of increased
testicular cancer, reproductive abnormalities, breast cancer, early
puberty and decreased sperm count have all been suggested as
problems possibly related to low-level exposure to chemicals
(pharmaceuticals and EDCs) in the environment.”46 Additional
research is needed regarding the effects of long-term, low-dose
exposure to PPCPs.47

B.2.1. Long-term Low-dose Exposures
As noted above, short-term exposure to low levels of specific
PPCPs does not appear to result in adverse human health impacts.
However, as Kolpin, et al., have noted:
For many [organic wastewater contaminants], acute effects
to aquatic biota appear limited because of the low
concentrations generally occurring in the environment.
More subtle, chronic effects from low-level environmental
exposure to select [organic wastewater contaminants] appear
to be of much greater concern. Such chronic effects have

B.2.2. Cumulative or Synergistic Effects
Human and environmental exposures to PPCPs are never to
a specific PPCP. Such exposures are always to combinations of

compounds through prescription and nonprescription medications, food and beverages, occupational exposures, and residential
activities (e.g., cleaning products, personal care products, hobby chemicals, pesticides). Moreover, the concentrations of some
potential EDCs (e.g., plasticizers) are orders of magnitude greater in food products than in drinking waters[.]
American Water Works Association Research Foundation, supra note 16, at xxii-xxiii. As Stanford, et al. have concluded, “the exposure
to natural estrogens and other suspected EDCs from drinking water pales in comparison to exposure through other dietary routes. …
[Furthermore,] compared with air exposure, water consumption by humans may represent only a small fraction of pharmaceutical, personal
care products, and EDC exposure.” Stanford et al., supra note 11, at 61, 63.
44

See, e.g., Schulman et al., supra note 13, at 669:
The main finding of this study was that detected levels of the compounds of interest (parent compounds, acetylsalicylic
acid, clofibrate, cyclophosphamide, and indomethacin, as well as the metabolites, salicylic acid and clofibric acid) in surface
waters and drinking water, do not pose a risk to human health. The concentrations of each of these pharmaceuticals found in
various environmental media to date, fall well below the provisional safe water quality limits derived, according to the [U.S.
Environmental Protection Agency’s Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health
(2000)]. Thus, no adverse health effects for humans are anticipated from the levels measured.

Accord Global Water Research Coalition, supra note 31, at 2 (“to date no definitive link between pharmaceutical exposure in drinking water
and human health risk has been reported nor established”); Rapid Public Health Policy Response Project, supra note 26, at 1 (“At current
levels, pharmaceutical residues are unlikely to pose an immediate risk to human health, but the long-term consequences of individual
chemicals, and combinations of chemicals, are unknown, especially as concentrations rise.”).
45

Kolpin et al., supra note 17, at 1208 (citations omitted).

46

Reynolds, Concern of Pharmaceuticals in Drinking Water, supra note 33, at 2.

“Although a wealth of toxicological information may be available for pharmaceuticals, the effects of unintended chronic exposure to
subtherapeutic doses that could occur via consumption of drinking water are often not known.” Erin M. Snyder et al., Pharmaceuticals and
EDCS in the US Water Industry – An Update, 97 Journal of the American Water Works Association 32, 33 (2005). Accord Ellis,
supra note 30, at 186.
47
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PPCPs, the impacts of which are relatively unknown.48

The issue of mixtures, that is the simultaneous presence
of multiple pharmaceuticals, is an ever present question
for trace residual compounds of all types in drinking
water supplies. The guidelines for “provisionally safe”
or “acceptable intake” levels are calculated separately
for individual compounds. However, the “worst case
scenario” approach used in screening risk assessment
includes large uncertainty factors and safety factors
and is considered by regulatory and health authorities
(e.g., the World Health Organization in their Drinking
Water Quality Guidelines) to be sufficient to account for
possible interactions among compounds a person might
be exposed to simultaneously.52

Combinations of PPCPs may have cumulative or synergistic
effects that go beyond the effects of any single PPCP. This led
Kolpin, et al., to conclude:
[A]dditional research on the toxicity of the target
compounds should include not only the individual
[organic wastewater contaminants] but also mixtures of
these compounds. The prevalence of multiple compounds
in water resources has been previously documented for
other contaminants. In addition, research has shown
that select chemical combinations can exhibit additive or
synergistic toxic effects, with even compounds of different
modes of action having interactive toxicological effects.49

Nevertheless, in addition to cumulative or synergistic effects,
recent research suggests that PPCPs may become more persistent if
they are combined. As Monteiro and Boxall have observed:

For example, in a study of the role of steroidal estrogens
in determining sex, the researchers noted that “strong natural
estrogens at low doses may synergize with low doses of weak
natural and man-made estrogens.”50 This combination of low doses
of estrogen “may act synergistically to produce a strong estrogenic
response.”51

As pharmaceuticals will never be in the environment
as single compounds, a consideration of the impacts
of mixtures of different pharmaceuticals and
pharmaceuticals and other compounds needs to be
assessed. Our preliminary data demonstrate that
degradation may be significantly slower in mixtures[.] 53

Other research suggests that cumulative or synergistic effects
may not be a threat to human health:

“In field situations, organisms are exposed to not just one compound but a mélange of contaminants, which can interact within the
environment and individual organisms.” Poynton & Vulpe, supra note 34, at 91. “[I]t is not clear what toxicological implications chronic
exposure to suites of trace contaminants may pose.” Mark J. Benotti et al., Pharmaceuticals and Endocrine Disrupting Compounds in U.S.
Drinking Water, 43 Environmental Science & Technology 597 (2009) (emphasis added) (citing Oliver A. Jones et al., Pharmaceuticals:
a Threat to Drinking Water, 23 Trends in Biotechnology 163 (2005); Shane A. Snyder et al., Pharmaceuticals, Personal Care Products,
and Endocrine Disruptors in Water: Implications for the Water Industry, 20 Environmental Engineering Science 449 (2003)).
“A limited body of research … suggests an additive effect when a mixture of pharmaceuticals is present.” Rapid Public Health Policy
Response Project, supra note 26, at 4 (citing Francesco Pomati et al., Effects and Interactions in an Environmentally Relevant Mixture of
Pharmaceuticals, 102 Toxicological Sciences 129 (2008)).
48

Kolpin et al., supra note 17, at 1210. In a study of the effect on aquatic and terrestrial species of exposure to tricolsan and tricolcarban,
Chalew and Halden concluded that “it appears prudent to consider the possibility of additive, antagonistic or synergistic effects from
exposure to mixtures of the two.” Talia E. Chalew & Rolf U. Halden, Environmental Exposure of Aquatic and Terrestrial Biota to Triclosan
and Triclocarban, 45 Journal of the American Resources Association 4, 11 (2009). It has also been noted that “[m]ixtures of
pharmaceuticals, which commonly occur in surface waters where discharges from municipal wastewater treatment plants flow, may have
cumulative effects on organisms.” TDC Environmental, Household Pharmaeutical Waste: Regulatory and Management Issues
2 (2004) (citing S.M. Richards et al., Effects of pharmaceutical mixtures in aquatic microcosms, 23 Environmental Toxicology and
Chemistry 1035 (2004)). See also Jessica G. Davis, Antibiotics in the Environment, 24(3) Agronomy News 1, 2 (2004) (“Degradation
products and interactions among compounds have not been adequately evaluated and could result in synergistic toxic effects”).
49

Judith M. Bergeron et al., Developmental Synergism of Steroidal Estrogens in Sex Determination, 107 Environmental Health
Perspectives 93, 96 (1999).

50

51

Id.

52

Global Water Research Coalition, supra note 31, at 2.

Sarah C. Monteiro, & Alistair A.B. Boxall, Pharmaceuticals and Personal Care Products in the Environment: Factors Affecting the
Degradation of Pharmaceuticals in Agricultural Soils, 28 Environmental Toxicology and Chemistry 2546, 2553 (2009).

53
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For example, while the degradation of individual PPCPs
identified in Project 2 was relatively fast (half-lives of less than 30
days), the presence of two PPCPs in a simple mixture increased the
persistence of both PPCPs.54

Other groups such as the elderly, the infirm, or the
immunocompromised may also be unusually susceptible.57
Research regarding the impacts of exposure to PPCPs on these and
other population segments or groups is ongoing.

B.2.3. Susceptible Groups

B.2.4. Environmental Health Impacts

Specific population segments or groups may be unusually
susceptible to adverse effects from exposure to PPCPs. Children,
for example, are thought to be particularly susceptible as are
pregnant women.55 As Collier has noted:

Human beings are not exposed continuously to water
supplies containing PPCPs. The same cannot be said for aquatic
species, which by their very nature are continuously exposed to
water supplies containing PPCPs.58 Such species “are exposed
continually, over many generations, to the higher concentrations
of pharmaceuticals that linger in surface water.”59 This exposure
may result in “endocrine disruptions, reproductive effects and renal
deterioration in fish, among other damage.”60

[L]ong-term exposure to such chemicals, for example
in children, could potentially cause long-term changes
affecting organ systems and/or structural function. In
addition, exposure to pharmaceuticals during the fetal
period when many of the growth and development patterns
for later life are laid down, may induce subtle changes that
take years to manifest, but eventually have measurable
physiological, morphological, or cognitive effects.56

54

For example, with regard to both fish and other aquatic
vertebrates, the low-level presence of pharmaceutical estrogens 61
leads to “a suite of adverse effects” including:
• Feminization of males62

These results are discussed in greater detail in Section V.

Abby C. Collier, Pharmaceutical Contaminants in Potable Water: Potential Concerns for Pregnant Women and Children, 4 EcoHealth
164, 170 (2007). Collier makes reference to “the special populations of pregnant and pediatric individuals, where there is elevated risk
from exposure to several drugs that are contraindicated and to which exposure should, ideally, be nil.” Id. See also, Cunningham, Binks, &
Olson, supra note 41, at 40; Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25.
55

56

Collier, supra note 55, at 170.

57

Cunningham, Binks, & Olson, supra note 41, at 40.

“Exposure risks for aquatic organisms are much larger than those for humans[.]” Rapid Public Health Policy Response Project, supra
note 26, at 4 (citing Environmental Protection Agency, Pharmaceuticals and Personal Care Products (PPCPS)).
58

59

Id. at 4 (citing Environmental Protection Agency, Pharmaceuticals and Personal Care Products (PPCPS)).

Id. at 4 (citing Larry B. Barber et al., Chemical Loading into Surface Water Along a Hydrological, Biogeochemical, and Land Use Gradient:
A Holistic Watershed Approach, 40 Environmental Science & Technology 475 (2006); S.D. Richardson, Water Analysis: Emerging
Contaminants and Current Issues,” 79 Analytical Chemistry 4295 (2007); R. Triebskorn, Toxic Effects of the Non-Steroidal AntiInflammatory Drug Diclofenac Part II. Cytological Effects in Liver, Kidney, Gills and Intestine of Rainbow Trout (Oncorhynchus mykiss),
60

68 Journal of Aquatic Toxicology 151 (2004)).
61

Specifically, estrone (E1), 17ß-estradiol (E2), estriol (E3) and the synthetic estrogen, 17 ethinylestradiol.

Marlo K. Sellin et al., Estrogenic Compounds Downstream from Three Small Cities in Eastern Nebraska: Occurrence and Biological
Effect, 45 Journal of the American Water Resources Associaton 14 (2009) (citing Gordon C. Balch et al., Feminization of Female
Leukophore-Free Strain of Japanese Medaka (Oryzias latipes) Exposed to 17ß-Estradiol, 23 Environmental Toxicology and Chemistry
2763 (2004); F. Brion et al., Impacts of 17ß-Estradiol, Including Environmentally Relevant Concentrations, on Reproduction After Exposure
During Embryo-Larval-, Juvenile- and Adult-Life Stages in Zebrafish (Danio rerio), 68 Aquatic Toxicology 193 (2004); G.H. Panter et
al., Adverse Reproductive Effects in Male Fathead Minnows (Pimephales promelas) Exposed to Environmentally Relevant Concentrations of
the Natural Oestrogens, Oestradiol and Oestrone, 42 Aquatic Toxicology 243 (1998)).
62
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• Impaired reproductive capacity63

The effects of PPCPs in water resources may be felt throughout
the food web. Chalew and Halden note that “[m]any of the
investigated organisms are at the bottom of the food chain;
therefore, impacts to their populations, due to either die-off
from acute toxic exposures or failure to reproduce successfully as
a result of chronic exposures, may lead to adverse consequences
throughout the ecosystem and food chain.”67 However, they also
note that “such a scenario at present is entirely speculative, since
studies appropriate to probe for this outcome have not yet been
conducted.”68

• Abnormal sexual development64
These observations led Sellin, et al. to conclude that “the
presence of estrogens in the aquatic environment, even at low
concentrations, is likely to pose a significant threat to the health of
aquatic organisms.”65
Such threats are not limited to the presence of low-levels of
pharmaceutical estrogens. Antidepressants, for example, may “trigger
premature spawning in shellfish while drugs designed to treat heart
ailments block the ability of fish to repair damaged fins.”66

Sellin et al., supra note 62, at 14-15 (citing Shoko Imai et al. Effects of 17ß-Estradiol on the Reproduction of Java-Medaka (Oryzias
Javanicus), a New Test Fish Species, 51 Marine Pollution Bulletin 708 (2005); F. Brion et al., Impacts of 17ß-Estradiol, Including
63

Environmentally Relevant Concentrations, on Reproduction After Exposure During Embryo-Larval-, Juvenile- and Adult-Life Stages in
Zebrafish (Danio rerio), 68 Aquatic Toxicology 193 (2004); Tsutomu Shioda & Meiko Wakabayashi, Effect of Certain Chemicals on
the Reproduction of Medaka (Oryzias latipes), 40 Chemosphere 239 (2000); V.J. Kramer et al., Reproductive Impairment and Induction
of Alkaline-Labile Phosphate, a Biomarker of Estrogen Exposure, in Fathead Minnows (Pimephales Promelas) Exposed to Waterborne
17ß-Estradiol, 40 Aquatic Toxicology 335 (1998)). Accord Poynton & Vulpe, supra note 34 (citing Karen A. Kidd et al., Collapse of
a Fish Population After Exposure to a Synthetic Estrogen, 104 Proceedings of the National Academy of Sciences of the United
States of America 8897 (2007) (17 ethynylestradiol has been shown “to cause sublethal effects in fathead minnow leading to population
decline at very low concentrations”)); Heiko L. Schoenfuss et al., Effects of Exposure to Low Levels of Water-Borne 17-Estradiol on Nest
Holding Ability and Sperm Quality in Fathead Minnows, 120 Water Resources Update 49 (2001). While exposure to 17ß-estradiol did
not result in long-term changes in sperm quality, the authors noted that 17-estradiol “is but one of many estrogenic compounds that have
been found in [sewage treatment plant] effluent, and the overall estrogenic potency of the effluent could be much greater than simulated in
this experiment.” Id. at 52. See also Schulman et al., supra note 13, at 676.
Sellin et al., supra note 62, at 15 (citing Narisato Hirai et al., Feminization of Japanese Medaka (Oryzias latipes) Exposed to 17betaEstradiol: Formation of Testis-Ova and Sex-Transformation During Early-Ontogeny, 77 Aquatic Toxicology 78 (2006); Henrik Holbech
et al., Detection of Endocrine Disrupters: Evaluation of a Fish Sexual Development Test (FSDT), 144C Comparative Biochemistry and
Physiology 57 (2006); W.R. Hartley et al., Gonadal Development in Japanese Medaka (Oryzias latipes) Exposed to 17ß-Estradiol, 46
Marine Environmental Research 145 (1998)).
64

65

Id.

66

Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25.

67

Chalew & Halden, supra note 49, at 10.

68

Id. The need for “appropriate” studies has been noted frequently. For example, Poynton & Vulpe have observed:
For many emerging contaminants, their toxicity to aquatic organisms is largely unknown. Even pharmaceuticals, which undergo
extensive testing in mammalian models, may exhibit different toxicity on aquatic species. In addition, many pharmaceuticals
and EDCs are not responsive to traditional toxicity assays that measure lethality or reproduction over a single generation and are
requiring regulatory agencies to rethink testing requirements. This could also be true for other emerging chemicals including
PBDEs [polybrominated diphenyl ethers] and nanomaterials whose mechanism of action is not known.

Poynton & Vulpe, supra note 34, at 84 (citing Mark C. Crane et al., Chronic Aquatic Environmental Risks From Exposure to Human
Pharmaceuticals, 367 Science of the Total Environment 23 (2006); Leon E. Gray, Jr. Tiered Screening and Testing Strategy for
Xenoestrogens and Antiandrogens, 102-103 Toxicology Letters 677 (1998); John P. Sumpter, & Andrew C. Johnson, Lessons From
Endocrine Disruption and Their Application to Other Issues Concerning Trace Organics in the Aquatic Environment, 39 Environmental
Science & Technology 4321 (2005)).
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The presence of antibiotics in water supplies may also reduce
the growth of aquatic plants.69 In essence, “since pharmaceuticals
is one of the few chemical classes intended to be bioactive, they are
potentially harmful to the aquatic flora and fauna.”70

There are, of course, some naturally occurring sources of
PPCPs. These sources appear as background amounts, not as major
PPCP sources. The major sources of PPCPs are anthropogenic.71
Assuming the use of pharmaceuticals, personal care products,
dietary supplements, and other consumer products, PPCPs
are contained in human and animal feces and urine. They are
also commonly contained in hospital or medical wastes and in
the wastes from industrial and agricultural processes. Another
common source of PPCPs is unwanted pharmaceuticals and
personal care products that are disposed of inappropriately (i.e.,
by being flushed down toilets.) 72 Pharmaceuticals used in the
fruit production industry are yet another source of PPCPs,73 as is
leachate from landfills74 and urban runoff.75 PPCPs may also be
rinsed from a person’s body during bathing.76

B.3. Sources of PPCPs in Water
An understanding of the sources of PPCPs in water is essential for
two reasons. First, as discussed in greater detail in the following
section, different statutory and regulatory requirements apply to
different sources of PPCPs. Second, as discussed in greater detail in
Section IV, potential alternative strategies leading to the minimization
or elimination of PPCPs in water may be source-specific.

TDC Environmental, supra note 49, at 2 (citing Richard A. Brain et al., Effects of 25 pharmaceutical compounds to Lemna gibba using a
seven-day static-renewal test, 23 Environmental Toxicology and Chemistry 371 (2004)).
69

Wennmalm & Gunnarsson, supra note 41, at 291. Accord Ellis, supra note 30, at 188 (“The persistent, long-term chronic exposure of
aquatic organisms to low-dose PPCP concentrations although individually at or below the [Probable No-Effects Concentration] level, may
well lead to cumulative stress and toxicity which could be a catalyst for subtle endpoint ecological changes.”).
70

With regard to EDCs, for example, see Ed Means, Amlan Ghosh & Zaid Chowdhury, Endocrine Disruptors and
Pharmaeceuticals Strategic Initiative Expert Workshop Report (Awwa Research Foundation 2007), (“while some estrogenic
compounds occur naturally, nost of the detected estrogenic compounds are introduced from man-made sources”). See also Dore Hollander,
Environmental Effects on Reproductive Health: The Endocrine Disruption Hypothesis, 29 Family Planning Perspectives 82, 83 (2007):
71

Endocrine disrupters, some of which occur naturally (phytoestrogens) and some of which are man-made, are ubiquitous: They can
be found in soil, water, air and food, as well as in commonly used industrial and household products. Phytoestrogens are present
in grains, legumes, grasses, herbs, nuts and a variety of fruits and vegetables; some fungi also produce compounds that may
interfere with hormonal function. Phytoestrogens are weaker than endogenous estrogen (i.e., they do not bind as well to hormone
receptors) and are quickly excreted or broken down into other compounds; they do not accumulate in body tissue.
Paul D. Anderson et al., Screening Analysis of Human Pharmaceutical Compounds in U.S. Surface Waters, 38 Environmental Science
& Technology 838 (2004). Accord Ellis, supra note 30, at 185.
72

Thomas Heberer et al., Occurrence and Fate of Pharmaceuticals During Bank Filtration - Preliminary Results From Investigations in
Germany and the United States, 120 Water Resources Update 4, 5 (2001) [hereinafter Heberer et al., Pharmaceuticals During Bank
Filtration].
73

74

Benotti et al., supra note 48. Accord Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25.

Juliane B. Brown, William A. Battaglin & Robert E. Zuellig, Lagrangian Sampling for Emerging Contaminants Through an Urban
Stream Corridor in Colorado, 45 Journal of the American Water Resources Association 68 (2009); Benotti et al., supra note 48.
75

76

Snyder et al., supra note 47, at 32.

14

B.4. Processes or Mechanisms by Which PPCPs are
Introduced Into Water Supplies

the treated water discharged into a receiving stream or lake78
and the residual sludge79 will contain varying levels of PPCPs.
Consequently, it is not surprising that a number of studies have
noted the increased presence of PPCPs in receiving waters
downstream of wastewater treatment plants.80 As discussed in
greater detail in Section V, treated wastewater used for agricultural
and landscape irrigation may also contain PPCPs.81

There are numerous processes or mechanisms by which PPCPs
are introduced into water supplies.77 With regard to the sources
of PPCPs noted above, a substantial portion of human wastes
are treated at wastewater treatment plants. Following wastewater
treatment plant processing, treated water may be discharged into a
receiving stream or lake.

In fact, only a portion of the wastes collected by sanitary
sewers may actually be treated at wastewater treatment plants.
Depending on the condition of the sewer system, a significant
portion of collected wastes may be lost through cracks or breaks
in sewer lines. In areas where storm drains and sanitary sewers

Typically, residual sludge contained in the processing tanks
of the wastewater treatment plant is removed and disposed
of pursuant to the regulations discussed in Section III. Both

“Pharmaceutical compounds are introduced into the environment through a number of different pathways, including excretion
of the parent compound, active ingredients, water soluble conjugates, or metabolites via urine and feces after therapeutic home and
hospital use, and through disposal of unused pharmaceuticals by patients or providers via landfills and sewers.” Schulman et al., supra
note 13, at 658 (citing N.J. Ayscough et al., The Environment Agency Research and Development Dissemination Centre, Review
of Human Pharmaeuticals in the Environment 106 (2000)). Accord Janice M. Skadsen et al., The Occurrence and Fate of
Pharmaceuticals, Personal Care Products and Endocrine Disruption Compounds in a Municipal Water Use Cycle:
Case Study in the City of Ann Arbor 2 (2004), available at http://www.a2gov.org/government/publicservices/water_treatment/
Documents/EndocrineDisruptors.pdf (“the potential exists for PPCPs to enter the environment from multiple routes, such as, wastewater
treatment discharge, industrial discharge, runoff from confined animal feeding operations, and treated sludge applied to agricultural
land…PPCPs may enter the treatment process in a reduced form (after passing through body) or by direct discharge of discarded PPCPs”)
(citing Christian G. Daughton & Thomas A. Ternes, Pharmaceuticals and Personal Care Products in the Environment: Agents of Subtle
Change? 107 Environmental Health Perspectives 1 (1999)).
77

Treated wastewater frequently contains “antioxidants, detergents and detergent metabolites, disinfectants, fire retardants, fragrances,
insect repellants, pharmaceuticals (prescription and nonprescription drugs), pesticides, plasticizers, polycyclic aromatic hydrocarbons,
and steroidal compounds[.]” Brown, Battaglin, & Zuellig, supra note 75, at 69-70. Such wastewater “has been shown to contain low, yet
biologically active, concentrations of estrogenic compounds.” Sellin et al., supra note 62, at 15 (citing Marta Carballa et al., Behavior of
Pharmaceuticals, Cosmetics and Hormones in a Sewage Treatment Plant, 38 Water Research 2918 (2004); Andrew C. Johnson & John P.
Sumpter, Removal of Endocrine-Disrupting Chemicals in Activated Sludge Treatment Works, 35 Environmental Science & Technology
4697 (2001); Chiara Baronti et al., Monitoring Natural and Synthetic Estrogens at Activated Sludge Sewage Treatment Plants and in a
Receiving River Water, 34 Environmental Science & Technology 5059 (2000)). See also Chalew & Halden, supra note 49, at 7; Kinney
et al., supra note 26, at 317 (citing Christian G. Daughton, & Thomas A. Ternes, Pharmaceuticals and Personal Care Products in the
Environment: Agents of Subtle Change? 107 Environmental Health Perspectives 907 (1999)).
78

“In biosolids destined for land application, a number of pharmaceuticals and personal care products have been detected.” Monteiro &
Boxall, supra note 53, at 2546 (citing Chad A. Kinney et al., Survey of Organic Wastewater Contaminants in Biosolids Destined for Land
Application, 40 Environmental Science & Technology 7207 (2006); Chris D. Metcalfe, Distribution of Acidic and Neutral Drugs in
Surface Waters Near Sewage Treatment Plants in the Lower Great Lakes, Canada, 22 Environmental Toxicology and Chemistry 2881
(2003)). See also M. Silvia Diaz-Cruz et al., Environmental Behavior andAanalysis of Veterinary and Human Drugs in Soils, Sediments,
and Sludge, 22 Trends in Analytical Chemistry 340 (2003).
79

Sellin et al., supra note 62, at 18 (greatest quantities of estrogens found in surface water downstream of wastewater treatment plants).
“[P]harmaceutical and PPCP residues have been detected in fish tissues downstream of wastewater treatment facilities leading to
bioaccumulation in muscles and critical organs.” Poynton & Vulpe, supra note 34, at 84 (citing Bryan W. Brooks et al., Determination
of Select Antidepressants in Fish From an Effluent-Dominated Stream, 24 Environmental Toxicology and Chemistry 464 (2005);
J. Schwaiger et al., Toxic Effects of the Non-steroidal Anti-inflammatory Drug Diclofenac. Part 1: Histopathological Alterations and
Bioaccumulation in Rainbow Trout, 68 Aquatic Toxicology 141 (2004)). Accord Brown, Battaglin, & Zuellig, supra note 75.
80

81

Kinney et al., supra note 26. Accord Benotti et al., supra note 48.
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are combined, significant rainfall events may produce quantities
of wastes that exceed the capacity of the wastewater treatment
plant.82 These “combined sewer overflows” (CSOs) are frequently
discharged into surface waters with little or no treatment, resulting
in “elevated concentrations of bacteria, nutrients, and OWCs
[organic wastewater compounds] in receiving waters.”83 As a
result, untreated sewage “derived from leaky sewers and CSOs
. . . may have a disproportionately large effect on concentrations
of compounds that are well removed by wastewater treatment
processes (such as caffeine and ibuprofen).”84

If the surface water is diverted subsequently for use as water
supply, a portion of the PPCPs contained in the raw water supply
will end up in the drinking water supply. If surface water is used to
recharge groundwater, or if the surface stream is a “losing” stream
that recharges groundwater, PPCPs in the surface stream may end
up in the groundwater.85 If the sludge from the processing tanks is
applied to land, a common disposal method in the United States
for wastewater treatment plant sludge, 86 then rain or melting snow
will allow the PPCPs to be absorbed into soils 87 and to infiltrate
groundwater.88

With regard to such weather events, Wu et al. have noted that the release of bacteria (and presumably PPCPs) trapped in sediments may
result from “sediment resuspension caused by storms, flood, tides, or strong winds[.]” Jianyong Wu et al., Fate and Transport Modeling of
Potential Pathogens: The Contribution from Sediments, 45 Journal of the American Water Resources Association 35, 36 (2009)
(citing R.W. Muirhead et al., Faecal Bacteria Yields in Artificial Flood Events: Quantifying In- Stream Stores, 38 Water Research 1215
(2004); R.C. Jamieson et al., Resuspension of Sediment- Associated Escherichia Coli in a Natural Stream, 34 Journal of Environmental
Quality 581 (2005)). On a related point, Guo and Krasner have noted a relationship between climatic variability and the variable presence
of PPCPs in water resources. Guo & Krasner, supra note 33, at 64 (reduced instream flow during dry years resulting in less dilution of
wastewater treatment plant outflows).
82

P. Phillips, & A. Chalmers, Wastewater Effluent, Combined Sewer Overflows, and Other Sources of Organic Compounds to Lake
Champlain, 45 Journal of the American Water Resources Association 45, 46 (2009). Accord Brown, Battaglin, & Zuellig, supra
note 75, at 70 (storm drains as a source of PPCPs).
83

Phillips & Chalmers, supra note 83, at 46 (citing Lorien J. Fono, & David L. Sedlak, Use of the Chiral Pharmaceutical Propranol to
Identify Sewage Discharges Into Surface Waters, 39 Environmental Science & Technology 9244 (2005)).

84

Thomas Heberer et al., Removal of Pharmaceutical Residues and Other Persistent Organics From Municipal Sewage and Surface Waters
Applying Membrane Filtration, 120 Water Resources Update 18, 19 (2001) [hereinafter Heberer et al., Removal of Pharmaceutical
Residues] (citations omitted).
85

See Committee on Toxicants and Pathogens in Biosolids Applied to Land, supra note 42, at 1 (“Approximately 5.6 million dry tons of
sewage sludge are used or disposed of annually in the United States; approximately 60% of that is used for land application.”). See also Xia
et al., supra note 4, at 47 (“Biosolids land application is becoming the most common means of biosolids disposal as other disposal options
become cost prohibitive or heavily regulated”).
86

Lozano, et al., have observed that tricolsan (TCS, “an antimicrobial compound that is added to a wide variety of household and
personal care products”) “may be accumulated by earthworms after land application of biosolids.” Nuria Lozano et al., Fate of Triclosan
in Agricultural Soils After Biosolid Applications, 78 Chemosphere 760 (2010) (citing Chad A. Kinney et al. Bioaccumulation of
87

Pharmaceuticals and Other Anthropogenic Waste Indicators in Earthworms from Agricultural Soil Amended with Biosolid or Swine Manure,
42 Environmental Science & Technology 1863 (2008)). The potential consequences of such bioaccumulation are of note:
Since TCS is a bacteriostat, there is a real potential that concentrations in soils resulting from biosolid applications might affect
bacterial ecology of these systems. Especially since the ecological balance and competitive advantages of the multiple species
inhabiting any soil environment are very complex and any small advantage one microbe might achieve due to exposure to these
known bacteriostat could be amplified under these conditions.

Id. at 764 (2010). The sorption and degradation of PPCPs in soil is discussed in greater detail in Section V.
Concluding that several pharmaceutically active compounds “can be transported through the subsoil without any substantial attenuation[,]”
Heberer et al. focused on clofibric acid, “the pharmacologically active metabolite of the drugs clofibrate, etofyllin clofibrate, and etofibrate,
used as blood-lipid regulators in human health care.” Heberer et al., Pharmaceuticals During Bank Filtration, supra note 73, at 6-7.
88

[B]etween 1992 and 1995, clofibric acid … was detected at concentrations at the μg/Llevel in ground water samples collected
16

The presence of PPCPs in groundwater has also been detected
in areas where human wastes are treated using septic tank
systems.89 Human wastes containing PPCPs that flow into septic
tanks will eventually flow into groundwater.

way into groundwater.93 Of particular concern are both the land
application of manure and the collection of liquid wastes in lagoons
or ponds associated with Confined Animal Feeding Operations.94

Because of the widespread use of antibiotics in animal
husbandry,90 PPCPS are also present in the feces and urine of a
wide variety of domesticated animals. Manure produced by such
animals will contain PPCPs. As with the sludge from wastewater
treatment plants, manure is frequently applied to land as a waste
disposal mechanism. Also as with wastewater treatment plant
sludge, rain or melting snow will cause PPCPs contained in
manure to flow into groundwater.91

C. Current Means of Protecting Water
Supplies:
C.1. Common Law Remedies Sounding in Tort
The word “tort” is derived from the Latin tortus meaning
bent or crooked. Torts are private acts of civil wrongs in which an
injured plaintiff seeks compensation from an allegedly responsible
defendant. There are four tort theories, each of which is potentially
applicable to injuries allegedly relating to exposure to PPCPs.
It should be noted, however, that application of any of the four
theories, either individually or in combination with one another,
will be dependent on the facts of a specific case.

Much like septic tank systems but on a larger scale, liquid
wastes from domesticated animals may be collected in lagoons or
ponds.92 These impoundments are quite effective in providing a
means by which PPCPs contained in liquid wastes can find their

from former sewage irrigation fields near Berlin and in Berlin tap-water samples. It became evident that these residues were
caused by the infiltration of sewage effluents into the soil and that clofibric acid is a very mobilecompound that is not substantially
adsorbed in the subsoil and is leached easily into the aquifer. … In Germany, the first detections of clofibric acid in ground water
put focus on the presence of drug residues in the aquatic system as a new emerging issue andresearchers began to investigate the
occurrence and fate of pharmaceutical residues in the aquatic environment, during drinking-water purification, and in drinking
water samples.

Id. at 6 (citing T. Heberer & H.J. Stan, Vorkommen von polaren organischen Kontaminanten im Berliner Trinkwasser, 86 Vom Wasser 19
(1997); T. Heberer & H. J. Stan, Determination of Clofibric Acid and N-(Phenylsulfonyl)-sarcosine in Sewage, River and Drinking Water,
67 International Journal of Analytical Chemistry 113 (1996); Umweltbundesamt, Sachstandsbericht ZU Auswirkungen
der Anwendung von ClofibrinsÄure und anderen Arzneimitteln auf die Umwelt und die Trinkwasserversorgung.
(Umweltbundesamt 1996)). See also Huang et al., supra note 25, at 33 (“Land application of animal waste provides routes for agricultural
antibiotics to enter the aquatic environments, which may eventually reach drinking water supplies”).
89

Rapid Public Health Policy Response Project, supra note 26, at 1. Accord Kinney et al., supra note 26.

“About 90 percent of the approximately 2.5 million kg of antibiotics sold in the United States are given as growth-promoting and
prophylactic agents in sub-therapeutic doses instead of being used to treat active infections, thereby lowering the cost of animal care.”
Heberer et al., Pharmaceuticals During Bank Filtration, supra note 73, at 10 (citing Dana Kolpin et al., Pharm-Chemical Contamination
– Reconnaissance for Antibiotics in Iowa Streams, 1999, in Effects of Animal Feeding Operations on Water Resources and the
Environment. Proceedings of the Technical Meeting, Fort Collins, Colorado, August 30-September 1, 1999 (Franceska D.
Wilde et al. eds., U.S. Geological Survey 2000)). Accord Reynolds, Concern of Pharmaceuticals in Drinking Water, supra note 33, at 1 (“40
percent of antibiotics manufactured are fed to livestock as growth enhancers”).

90

91

Heberer et al., Pharmaceuticals During Bank Filtration, supra note 73, at 6. Accord Davis, supra note 49.

“Researchers have shown that several classes of antibiotics (e.g., tetracyclines, sulfonamides, macrolides and ionophores) are present in
hog waste lagoons at concentrations as high as 0.7 mg/L.” Carlson et al., supra note 26, at 4..

92

93

Heberer et al., Pharmaceuticals During Bank Filtration, supra note 73, at 10.

Benotti et al., supra note 48. See also, Ken Carlson et al., Antibiotics in Animal Waste Lagoons and Manure Stockpiles, Agronomy
News, Dec. 2004, at 7 (“a wide range of antibiotics is present in most animal waste streams, either runoff ponds, waste lagoons or manure
stockpiles”); Heberer et al., Pharmaceuticals During Bank Filtration, supra note 73, at 10; Masters, supra note 6.

94
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C.1.1. Trespass

Public nuisances result where a defendant (a) offended accepted
community principles of decency or (b) interfered with the use
of public highways, streams, parks, beaches or other facilities.99
Private nuisances result where the defendant (a) substantially
interfered with the plaintiff ’s use and enjoyment of property or (b)
injured the plaintiff.100

There are three elements for establishing a claim under the
theory of trespass. First, the plaintiff must have been harmed.95
Second, the defendant’s conduct must be shown to have been
the cause of the plaintiff ’s harm. Third, it must be proven that
the defendant intentionally (a) entered land in the possession of
the plaintiff (or caused something or someone else to do so); (b)
remained on the plaintiff ’s land; or (c) failed to remove from the
plaintiff ’s land “a thing which he is under a duty to remove.”96 In
the case of personal property (trespass to chattels), an alternative
third element is applicable where it can be shown that the
defendant intentionally interfered with the plaintiff ’s personal
property by (a) damaging the personal property; (b) depriving the
plaintiff of the use of the property for a substantial period of time;
or (c) “dispossessing” the property from the plaintiff.97 With regard
to the requirement of intentionality, individuals are generally
presumed to know the “natural consequences” of their actions.98

C.1.3. Negligence
There are five elements to the theory of negligence, all of which
must be established to raise a claim against a defendant. First,
the plaintiff must have been harmed. Second, the evidence must
show that the defendant’s conduct was the cause of the plaintiff ’s
harm. Third, it must be established that the defendant owed a duty
of reasonable care to the plaintiff.101 Fourth, the plaintiff must
evidence that the defendant breached the duty of reasonable care.
Fifth, the harm to the plaintiff resulting from the breach must be
shown to have been foreseeable.102
Of particular relevance is the duty of reasonable care. The
standard of care is frequently expressed as the question: What
would a reasonably prudent person have done? It is noteworthy
that professionals, because of both education and licensing
requirements, are usually held to a higher standard of care than
non-professionals.103 Corporations, because of superior knowledge
regarding specific products, may also be held to a higher standard
of care than the general citizenry.104

C.1.2. Nuisance
As with the theory of trespass, there are three elements
necessary to raise a claim under the theory of nuisance. First, the
plaintiff must establish that she was harmed. Second, the evidence
must show that the defendant’s conduct was the cause of the
plaintiff ’s harm. Third, it must be established that the defendant’s
intentional actions constituted either a public or a private nuisance.

Restatement (Second) of Torts §§ 158, 162, 901, 907 (1979). The plaintiff does not have to show harm for the defendant to be liable
for trespass. However, the plaintiff would have to show harm to receive compensatory damages, though there are other remedies, such as
nominal damages, that do not require a showing of harm.

95

Id. §158 . As noted in the Restatement, the protected property interest of the plaintiff is the right of “exclusive possession and physical
condition of land.” Id. § 157.
96

97

Id. §§ 217-18.

Francis v. Franklin, 471 U.S. 307, 311 (1985) (“A person of sound mind and discretion is presumed to intend the natural and probable
consequences of his acts …”).

98

99

See State v. H. Samuels Co., 211 N.W.2d 417 (Wis. 1973) (holding that a violation of a noise ordinance may constitute nuisance).

100

Restatement (Second) of Torts, supra note 96, at § 821D.

Reasonableness may be defined in permit conditions or by industry custom/practice. Violation of permit conditions or other statutory
or regulatory requirements is almost always negligence per se. See, e.g., Sammons v. Ridgeway, 293 A.2d 547 (Del. 1972) (holding that the
violation of a statute is negligence per se).
101

102

See, e.g., Palsgraf v. Long Island R.R. Co., 162 N.E. 99 (N.Y. 1928).

See, e.g., Blair v. Eblen, 461 S.W.2d 370 (Ky. 1970) (holding that a doctor is under a duty to use that degree of care and skill which is
expected of a reasonably competent doctor in the same class to which he belongs).
103

See, e.g., Binder v. Jones & Laughlin Steel Corp., 520 A.2d 863 (Pa. Super. Ct. 1987) (holding that manufacturer had an affirmative
duty to warn of risk due to its knowledge of the product’s properties).
104
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C.1.4. Strict Liability

C.2. Protection of Surface Water Quality: The
Clean Water Act

There are three elements to the theory of strict liability. The
first two are the same as for negligence, namely that the evidence
show that the plaintiff was harmed, and the defendant’s conduct
was the cause of plaintiff ’s harm. The third element requires a
showing that the defendant either engaged in an “abnormally
dangerous activity” or manufactured an inherently dangerous
product.105

The Clean Water Act (CWA) was intended to restore and
maintain the chemical, physical and biological integrity of the
nation’s water resources. 109 As enacted by Congress, the CWA
imposes a number of requirements intended to achieve these
objectives. Initially, states are authorized to designate water quality
standards or allowable uses of rivers located within the state.110
This designation may be in terms of water quality standards to
be maintained in the river, in terms of allowable uses, or both.111
However, these standards or designated uses, which are subject to
EPA approval, 112 must be based on the National Recommended
Water Quality Criteria.113

A number of factors must be considered in determining whether
the defendant’s activities are abnormally dangerous. These include
(a) a high degree of risk or harm; (b) the gravity of the harm; (c)
the possibility of eliminating the risk with reasonable care; (d)
whether the activity is in common usage; (e) the appropriateness of
the activity for the location where it occurred; and (f) the value of
the activity to the community. 106 If the defendant is engaged in an
abnormally dangerous activity, the defendant may be held strictly
liable for injuries resulting to the plaintiff irrespective of the degree
of care exercised by the defendant. 107

If a state chooses to utilize water quality standards, the standards
must include total maximum daily loads (TMDLs) for those pollutants
that are amenable to maximum daily load measurement.114 As discussed
below, TMDLs are to be a part of state water quality standards
applicable to the issuance of discharge permits.

As suggested above, the defendant may also be strictly liable
for injuries to the plaintiff resulting from an inherently dangerous
product manufactured by the defendant. Products may be
inherently dangerous due to design defects, manufacturing defects,
or marketing defects. 108

105

Once water quality standards or designated uses have been
approved, implementation is carried out through the National
Pollutant Discharge Elimination System (NPDES) permit
system.115 This system allows companies, governmental units,
and other entities to obtain an NPDES permit for the discharge

See Caporale v. C.W. Blakeslee & Sons, Inc., 175 A.2d 561 (Conn. 1961) (holding that construction under the circumstances was

“intrinsically dangerous”).
106

See RESTATEMENT (SECOND) OF TORTS, supra note 96, at § 402A..

See Rylands v. Fletcher, UKHL 1 (United Kingdom House of Lords Decisions, 1868) (mill owner who constructed a reservoir was liable
without fault when the reservoir failed and flooded an adjoining mine; mill owner was liability without fault for collecting “anything likely
to do mischief if it escapes”). See also Caporale, 175 A.2d at 564.
107

108

See Saupitty v. Yazoo Mfg. Co., 726 F.2d 657 (10th Cir. 1984) (holding that a lawnmower as designed was inherently dangerous);

MacPherson v. Buick Motor Co., 111 N.E. 1050 (N.Y. 1916) (finding that defects in the manufacture of a motor vehicle rendered it
inherently dangerous); Dunham v. Vaughn & Bushnell Mfg. Co., 247 N.E.2d 401 (Ill. 1969) (holding that a hammer was inherently
dangerous when used as advertised).
109

Clean Water Act, Pub. L. No. 92-500, 86 Stat. 816 (1972) (codified as amended at 33 U.S.C. § 1251 et seq. (2006)).

110

See 40 C.F.R. § 130.0 (2010).

111

PUD No. 1 of Jefferson County v. Washington Dep’t of Ecology, 511 U.S. 700 (1994).

112

See WESTVACO v. EPA, 899 F.2d 1383 (4th Cir. 1990). Such standards or designated uses may also be subject to EPA disapproval.

Id.
113

33 U.S.C. §§ 1313-1314.

114

§ 130.4.

115

CWA § 1342. 116 40 C.F.R. § 230.3(s) (2010).
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of effluent from a point source into “waters of the United
States.”116 Absent an NPDES permit, such discharges are strictly
prohibited.117

on public water systems. The National Primary Drinking Water
Regulations, one of the primary enforcement mechanisms of the
SDWA, apply to community water systems.124 Noncommunity
or transient water systems are smaller systems that usually rely on
groundwater.

NPDES permits contain specific provisions regarding the
type of waste treatment technology required and the type and
concentration of materials to be discharged.118 For existing
facilities, the general requirement is Best Cost-Reasonable
Technology (BCT).119 For new facilities, the requirement is Best
Available Technology.120

C.3.1. National Primary Drinking Water
Regulations
The National Primary Drinking Water Regulations are
health-based standards for drinking water supplied by public water
systems.125 These regulations are without exceptions. They apply
to contaminants that have been determined to pose public health
risks and are expressed in terms of Maximum Contaminant Levels
(MCLs).126 In general, “Best Available Technology” is required,
though cost is taken into consideration. 127 The technology
should result in a discharge as close as possible to the Maximum
Contaminant Level Goal (MCLG).128

C.3. Protection of Groundwater and Surface Water
Quality: The Safe Drinking Water Act
The primary objective of the Safe Drinking Water Act
(SDWA) is to identify, monitor, and control contaminants
in drinking water.121 The SDWA is also intended to provide
an enforcement mechanism, provide for the collection and
dissemination of water-related information, and provide funding
mechanisms to upgrade water supply systems.122

Both MCLs and MCLGs are to be based on human health
effects. Risk assessments are to be used to determine these effects.
In conducting such assessments, EPA is to utilize “the best
available, peer-reviewed science and supporting studies conducted
in accordance with sound and objective scientific practices”129 and
“data collected by accepted methods or best available methods (if

As with many environmental statutes, implementation of
the SDWA is an example of cooperative federalism. States have
primary enforcement authority once the state SDWA program has
been approved by the EPA.123 SDWA requirements focus primarily

117

See id.

118

Id. § 1342(p)(3).

119

40 C.F.R. § 125.3.

Id. EPA has issued New Source Performance Standards mandating the use of “best available demonstrated control technology” for a
number of industrial categories.

120

Safe Drinking Water Act (SDWA), Pub. L. No. 93-523, 88 Stat. 1660 (codified as amended at 42 U.S.C. § 300f (2006)); Daniel J.
Kucera, Safe Drinking Water Act, in Environmental Law Handbook 437, 439 (Thomas F.P. Sullivan ed., Government Institutes 19th
ed. 2007).
121

122

Kucera, supra note 121, at 439-40.

123

Id. at 440.

124

Community water systems are systems having at least 15 taps or providing service to at least 25 individuals. SDWA § 300f(15).

40 C.F.R. § 141.1 et seq .(2010). The National Primary Drinking Water Standards include 85 standards divided into six categories:
disinfectants, disinfection byproducts, inorganic chemicals, microorganisms, organic chemical, and radionuclides. Id.

125

SDWA § 300g-1(b)(1). MCLs may also be expressed in terms of treatment techniques if it is impossible to establish an MCL (i.e.,
difficulty in measuring or uncertainty regarding appropriate exposure limits). Id. § 300g-1(b)(7).

126

127

See id. § 300g-1(b)(4).

128

Id. § 300g-1(b)(4). MCLGs are health-based goals that do not take cost into consideration. See id. §§ 300g-1(b)(1), (4).

129

42 U.S.C. § 300g-1(b)(3)(A)(i).
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color, taste, odor), rather than its safety.137 The National Secondary
Drinking Water Regulations are not enforceable.138

the reliability of the method and the nature of the decision justifies
use of the data).”130
The process for establishing MCLGs is relevant vis-à-vis the
PPCP control options discussed in Section VI.131 With regard to
MCLGs for non-carcinogens, using the methodology noted above,
a substance-specific Reference Dose (RfD) is determined.132 In
general, depending on the availability of information about a specific
substance, the RfD is calculated by dividing Lowest-ObservedAdverse-Effect Level (LOAEL)133 or No-Observed-Adverse-Effect
Level (NOAEL)134 by an Uncertainty Factor (UF).135 The MCLG
is then determined by (a) multiplying the RfD by an assumed
body weight of 70 kg, (b) dividing by an assumed daily water
consumption of 2 liters to determine Drinking Water Equivalent
Level (DWEL) and (c) multiplying DWEL by an assumed daily
exposure attributed to the consumption of water.136

C.3.2. The Unregulated Contaminant Monitoring
Rule
The SDWA requires the EPA to both: (a) establish criteria
for a monitoring program for unregulated contaminants; and
(b) publish a list of contaminants to be monitored. 139 Based on
information developed through the monitoring program, the
EPA is to evaluate and prioritize unregulated contaminants for
potential inclusion on the Contaminant Candidate List discussed
below. 140 The Unregulated Contaminant Monitoring Rule 141 lists
contaminants that must be monitored by public water systems,
describes analytical methods of assessing these contaminants, and
requires the monitoring and analysis results to be submitted to the
EPA for inclusion in the National Drinking Water Contaminant

The SDWA also authorizes National Secondary Drinking
Water Regulations which relate to the aesthetics of water (i.e.,

130

Id. § 300g-1(b)(3)(A)(ii).

131

Infra, note 229 and associated text.

Reference Dose is defined as “[a]n estimate of a daily oral exposure for a given duration to the human population (including susceptible
subgroups) that is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived from a BMDL [Benchmark
Dose Level], a NOAEL [No- Observed-Adverse-Effect Level], a LOAEL [Lowest-Observed-Adverse-Effect Level], or another suitable
point of departure, with uncertainty/variability factors applied to reflect limitations of the data used.” Environmental Protection Agency,
Integrated Risk Information System (IRIS), http://www.epa.gov/iris/gloss8_arch.htm (last visited Feb. 9, 2011).

132

Lowest-Observed-Adverse-Effect Level is defined as “[t]he lowest exposure level at which there are statistically or biologically
significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control group.” Id.

133

No-Observed-Adverse-Effect Level is defined as the “highest exposure level at which there are no statistically or biologically significant
increases in the frequency or severity of adverse effect between the exposed population and its appropriate control; some effects may be
produced at this level, but they are not considered adverse, nor precursors to adverse effects.” Id.

134

“Uncertainty Factor” is defined as “[o]ne of several, generally 10-fold factors, used in operationally deriving the RfD [Reference Dose]
and RfC [Reference Concentration] from experimental data. UFs are intended to account for (1) the variation in sensitivity among the
members of the human population, i.e., interhuman or intraspecies variability; (2) the uncertainty in extrapolating animal data to humans,
i.e., interspecies variability; (3) the uncertainty in extrapolating from data obtained in a study with less-thanlifetime exposure to lifetime
exposure, i.e., extrapolating from subchronic to chronic exposure; (4) the uncertainty in extrapolating from a LOAEL rather than from a
NOAEL; and (5) the uncertainty associated with extrapolation from animal data when the database is incomplete.” Id.
135

Environmental Protection Agency, Regulating Public Water Systems and Contaminants Under the Safe Drinking Water Act, http://
water.epa.gov/lawsregs/rulesregs/regulatingcontaminants/basicinformation.cfm (last visited Feb. 9, 2011).

136

137

Kucera, supra note 121, at 445.

138

40 C.F.R. § 143.1 (2010).

139

Kucera, supra note 121, at 477.

140

Id.

141

Unregulated Contaminant Monitoring Rule, 64 Fed. Reg. 50,556 (Sept. 17, 1999) (codified at 40 C.F.R. §§ 9, 141-42).
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Occurrence Database. Public water systems are also required
to notify their consumers of the results of the monitoring and
analysis. 142 The goal of the Unregulated Contaminant Monitoring
Rule is to ensure that decisions regarding the regulation of specific
contaminants are based on sound science, not political influence.143

Cryptosporidium (99% removal), Giardia lamblia (99.9% removal or
inactivation), and viruses (99.99% removal or inactivation).147

C.3.5. The Wellhead Protection Program
Amendments to the SDWA in 1986 enhanced the protection of
underground sources of drinking water by authorizing the wellhead
protection program. 148 Under the SDWA as amended, states
were required to develop wellhead protection programs within
three years and submit them to the Administrator of the EPA for
approval. 149 The goal of the wellhead protection program was to
“protect wellhead areas . . . from contaminants which may have any
adverse effect on the health of persons[.]” 150

C.3.3. The Contaminant Candidate List
The SDWA 144 also requires the EPA to publish a Contaminant
Candidate List every five years. This list must include contaminants
that are not currently subject to National Primary Drinking Water
Regulations but are known or anticipated to occur in public water
systems. 145 The SDWA specifies three criteria to be utilized
in determining whether a contaminant may be a candidate for
regulation: (1) The contaminant may have an adverse effect on the
health of persons; (2) The contaminant is known to occur, or there
is a substantial likelihood that the contaminant will occur in public
water systems with a frequency and at levels of public health concern;
and (3) In the sole judgment of the Administrator, regulation of
such contaminant presents a meaningful opportunity for health risk
reduction for persons served by public water systems.146

To encourage the states to develop wellhead protection
programs, Congress provided both an incentive and a disincentive.
As an incentive, the SDWA provided that the activities of federal
agencies having an effect on the wellhead protection area must
be consistent with the states’ wellhead protection programs. 151
As a disincentive, the SDWA provided that failure to develop
an acceptable wellhead protection program would result in state
ineligibility for certain federal funding to implement the wellhead
protection program.152

C.3.4. The Surface Water Treatment Rule
The SDWA also contains a Surface Water Treatment Rule which
requires systems using surface water or groundwater under the direct
influence of surface water to disinfect and filter their water so that
the following contaminants are controlled at the following levels:

C.3.6. The Underground Injection Control Program
Protection of underground sources of drinking water also
occurs through the SDWA’s Underground Injection Control

142

Kucera, supra note 121, at 457.

143

See SDWA § 300g-1(b).

144

Id.

145

Id.

146

SDWA § 300g-1(b)(1)(A); see Kucera, supra note 121, at 447.

147

Surface Water Treatment Rule, 40 C.F.R. § 141.70 (2010); see SDWA § 300g-1(b)(2)(C).

148

SDWA § 300h-7.

149

Id. § 300h-7(a).

“Wellhead protection areas” were defined as “the surface and subsurface area surrounding a water well or wellfield, supplying a public
water system, through which contaminants are reasonably likely to move toward and reach such water well or wellfield[.]” Id. § 300h-7(e).

150

151

Id. § 300h-7(h).

152

Id. § 300h-7(d).
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Program (UICP). 153 The UICP was mandated by ongoing reliance
on groundwater as a source of drinking water supplies. 154 Over
80% of community water systems rely on groundwater for all or
part of their water supply. 155

• Class V wells include all injection wells that are not
included in Classes I-IV.
• Class VI wells are used for injection of carbon dioxide.

With regard to well construction, the UICP both required permits
and established standards based on different classes of wells: 156

C.3.7. The Biosolids Rule

• Class I wells are used for injection of industrial nonhazardous liquids, municipal wastewaters, or hazardous
wastes beneath the lowermost underground source of
drinking water.

The Clean Water Act Amendments of 1987 required EPA
to promulgate regulations to protect public health and the
environment from adverse impacts associated with the disposal
of biosolids (i.e., the sludge from wastewater treatment plants).
These regulations were published in 1993 157 and became Title 40,
Part 503 of the Code of Federal Regulations. As a result, they are
commonly known as the “Part 503 Biosolids Rule.”

• Class II wells are used for injection of fluids in
connection with conventional oil or natural gas
production, enhanced oil and gas production, and the
storage of hydrocarbons which are liquid at standard
temperature and pressure.

Of particular relevance to the issue of PPCPs in water supplies
is that portion of the Biosolids Rule relating to the application of
biosolids to land. 158 Four general requirements are established
under the Biosolids Rule. First, ceiling concentration limits were
established for heavy metals. 159 Second, pollutant loading rate
limits were formulated. Third, pathogen control requirements were

• Class III wells are used for injection of fluids associated
with the extraction of minerals or energy, including the
mining of sulfur and solution mining of minerals.
• Class IV wells are used for injection of hazardous or
radioactive wastes into or above underground source of
drinking waters.

153

Id. § 300h.

154

Kucera, supra note 121, at 474.

155

See id.

40 C.F.R. § 146.5 (2010). With regard to Class VI wells, see Federal Requirements Under the Underground Injection Control (UIC)
Program for Carbon Dioxide (CO2) Geologic Sequestration (GS) Wells, 75 Fed. Reg. 77,230 (December 10, 2010).

156

157

58 Fed. Reg. 9348 (February 19, 1993).

Other portions of Part 503 apply to a variety of different uses and disposal techniques for biosolids. See generally Office of Wastewater
Management, Environmental Protection Agency, A Plain English Guide to the EPA Part 503 Biosolids Rule (1994) [hereinafter
EPA Guide to Part 503 Biosolids Rule].

158

Ceiling concentration limits were established for arsenic, cadmium, chromium, copper, lead, mercury, molybdenum, nickel, selenium
and zinc. See Environmental Protection Agency, Chapter 2: Land Application of Biosolids in EPA Guide to Part 503 Biosolids Rule,
supra note 158, at 29. To establish these limits:

159

EPA conducted extensive risk assessments that involved identifying the chemical constituents in biosolids judged likely to pose
the greatest hazard, characterizing the most likely exposure scenarios, and using scientific information and assumptions to
calculate concentration limits and loading rates (amount of chemical that can be applied to a unit area of land). [However, there]
have been substantial advances in risk assessment since then, and there are new concerns about some adverse health outcomes and
chemicals not originally considered. Because of the diversity of exposed populations, environmental conditions, and agricultural
practices in the United States, it is important that nationwide chemical regulations be based on the full range of exposure
conditions that might occur. Furthermore, there is a need to investigate whether the biosolids produced today are similar in
composition to those used in the original assessments.
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ascertained. 160 Fourth, vector-attraction reduction requirements
were mandated. 161

One of the primary statutes dealing with hazardous substances
and wastes is the Resource Conservation and Recovery Act
(RCRA), which was enacted to establish a program for the “cradleto-grave” management of hazardous substances and waste. 164 One
of the goals of RCRA, as expressed in Subtitle A, is to protect
human health and the environment from the hazards posed by
waste disposal. 165 Other goals include the reduction or elimination
of the amount of waste generated (including hazardous waste) and
the proper management of such waste to protect human health and
the environment. 166

For land disposal to be permitted, all biosolids must comply
with the ceiling concentration limits for heavy metals. There are a
number of options available to fulfill the other three requirements.
These options are based on the characteristics of both the biosolids
and the land to which the biosolids are to be applied. 162 Once
biosolids have been applied to land, an ongoing monitoring
program is required. 163

Subtitle C of RCRA created a hazardous waste management
program. 167 A waste is considered “hazardous” if it is a solid waste,
defined as:

C.4. Protection of Groundwater and Surface Water
Quality by Regulating Hazardous Substances and
Wastes: The Resource Conservation and Recovery Act

Committee on Toxicants and Pathogens in Biosolids Applied to Land, supra note 42, at 2, 12. This led the National Research Council to
recommend:
[A] new national survey of chemicals in biosolids should be conducted. EPA should review available databases from state
programs in designing a new survey. Other elements that should be included in the survey are an evaluation of the adequacy
of detection methods and limits to support risk assessment; consideration of chemical categories, such as odorants and
pharmaceuticals, that were not previously evaluated[.]

Id. at 12 (emphasis added).
“In contrast to the chemical standards, the pathogen standards are not risk-based concentration limits for individual pathogens but
are technologically based requirements aimed at reducing the presence of pathogens and potential exposures to them by treatment or a
combination of treatment and use restrictions.” Committee on Toxicants and Pathogens in Biosolids Applied to Land, supra note 42, at
2. In fact, with regard to pathogens, the National Research Council has recommended use of improved risk assessment method: “Riskassessment methods for chemicals and pathogens have advanced over the past decade to the extent that (1) new risk assessments should
be conducted to update the scientific basis of the chemical limits, and (2) risk assessments should be used to supplement technological
approaches to establishing regulatory criteria for pathogens in biosolids.” Id. at 4.
160

161

Vectors are typically flies and rodents.

See Office of Wastewater Management, Environmental Protection Agency, A Guide to the Biosolids Risk Assessments for the
EPA Part 503 Rule (1995).The options include the Exceptional Quality option, the Pollutant Concentration option, the Cumulative
Pollutant Loading Rule option and the Annual Pollutant Loading Rate option. The requirements applicable to each option are discussed in
Chapter 2: Land Application of Biosolids, in EPA Guide to Part 503 Biosolids Rule, supra note 158, at 30-40. These requirements were
based on a comprehensive risk assessment.
162

Monitoring must include pollutants, pathogen densities (fecal coliform, salmonella, viable helminth ova and enteric virus) and vector
attraction reduction. See Chapter 2: Land Application of Biosolids, in EPA Guide to Part 503 Biosolids Rule, supra note 158, at 47-49;
Chapter 6: Sampling and Analysis, in EPA Guide to Part 503 Biosolids Rule, supra note 158, at 129-51.
163

Resource Conservation and Recovery Act of 1976 (RCRA; Solid Waste Disposal Act), Pub. L. No. 94- 580, 90 Stat. 2795 (codified
as amended at 42 U.S.C. §§ 6901-6992k (2006)); David R. Case, Resource Conservation and Recovery Act, in Environmental Law
Handbook 133, 134 (Thomas F.P. Sullivan ed., Government Institutes 19th ed. 2007).

164

165

RCRA § 6902(a).

166

Id.

167

Id.
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[A]ny garbage, refuse, sludge from a waste treatment
plant, water supply treatment plant or air pollution control
facility and other discarded material, including solid,
liquid, semisolid, or contained gaseous materials resulting
from industrial, commercial, mining and agriculture
activities and from community activities but does not
include solid or dissolved material in domestic sewage, or
solid or dissolved materials in irrigation return flows or
industrial discharges which are point sources subject to
permits under section 402 of the Federal Water Pollution
Control Act, as amended, or source, special nuclear, or
byproduct material as defined by the Atomic Energy Act
of 1954, as amended (68 Stat. 923). 168

• The “F” list – hazardous wastes from nonspecific
sources (e.g., spent nonhalogenated solvents, such as
toluene or methyl ethyl ketone).
• The “K” list – hazardous wastes from specific sources
(e.g., petroleum refining wastes or bottom sediment
sludge from the treatment of wastewaters by the wood
preserving industry).
• The “P” list – chemicals considered “acutely” hazardous
irrespective of concentration (e.g., nitric oxide).
• The “U” list – chemicals considered hazardous at higher
concentrations (e.g., acetone) Christenson notes that,
“[s]ince most hazardous pharmaceuticals are on the P-list or
Ulist, health-care facilities focus primarily on these lists.”172

Certain wastes are specifically excluded from the definition
of solid waste, including “(a) any mixture of domestic sewage
and other wastes that passes through a sewer system to a publicly
owned treatment works and (b) industrial wastewater discharges
that are point source discharges under the Clean Water Act.” 169

C.4.1. The Mixture Rule
In addition, the “mixture rule” provides that a mixture of a
listed hazardous waste and a solid waste must also be considered a
hazardous waste. 173 This rule may not apply if (a) the mixture does
not exhibit the characteristics for which the waste was considered
hazardous (ignitability, corrosivity, reactivity or toxicity), (b) the
mixture is regulated under the Clean Water Act, or (c) the mixture
contains only de minimis quantities of hazardous wastes. 174

Waste is considered hazardous if it is:
any solid waste, or combination of solid wastes, which
because of its quantity, concentration, or physical,
chemical, or infectious characteristics may (A) Cause, or
significantly contribute to an increase in mortality or an
increase in serious irreversible, or incapacitating reversible
illness; or (B) Pose a substantial present or potential
hazard to human health or the environment when
improperly treated, stored, transported, or disposed of, or
otherwise managed. 170

C.4.2. Categories of Generators
Hazardous waste generators are regulated depending on the
amount of waste they generate each month. 175 There are three
categories:

This statutory language gives the EPA broad authority to
define hazardous wastes through regulation. Applicable regulations
establish several lists of hazardous wastes: 171

• Large quantity generators (LQG, generators of more the
1,000 kilograms of hazardous waste per month)

168

Id. § 6903(27).

169

Case, supra note 164, at 138.

170

RCRA § 6903(5).

171

40 C.F.R. § 261.31, 261.32, Part 273 (2010); Case, supra note 164, at 141-42.

Teirney Christenson, Comment, Fish on Morphine: Protecting Wisconsin’s Natural Resources Through a Comprehensive Plan for Proper
Disposal of Pharmaceuticals, 2008 Wisconsin Law Review 141, 149 (2008) (citing Christian G. Daughton, Cradle-to-Cradle Stewardship

172

of Drugs for Minimizing Their Environmental Disposition While Promoting Human Health. II. Drug Disposal, Waste Reduction, and
Future Directions, 111 Environmental Health Perspectives 775, 782 (2003))
173

§ 261.3(a)(2); Case, supra note 164, at 145.

174

40 C.F.R. § 261.3 (2010).

175

40 C.F.R. Part 260 (2010); see Case, supra note 164, at 152-53.
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C.4.4. Treatment, Storage and Disposal Facilities

• Small quantity generators (SQG, generators of between
100 and 1,000 kilograms of hazardous waste per month)

Requirements for TSDFs are also established under RCRA. A
permit is required to construct and operate a TSDF. 181 The permit
contains specific operating standards and requirements applicable to
the TSDF. 182 The operator of a TSDF must demonstrate financial
responsibility (in case of accidents) as well as the capability to
close the TSDF in accordance with EPA regulations. 183 In terms
of remediation and corrective actions that might be required at a
TSDF, the owner or operator is responsible for investigating and,
when necessary, remediating releases from their facilities. 184

• Conditionally exempt small quantity generators
(CESQGs, generators of less than 100 kilograms of
hazardous waste per month)
Under RCRA, hazardous waste generators must comply with
regulations concerning record keeping and reporting, must observe
waste accumulation time limits, and must comply with storage
requirements. 176

A number of specific limitations and prohibitions are contained
in RCRA. Bulk (noncontainerized) hazardous liquid waste is
prohibited from disposal in any landfill. 185 There are also severe
restrictions on the disposal of containerized hazardous liquid
waste. 186 Land disposal of specific highly hazardous waste was
phased out between 1986 and 1990. 187

C.4.3. The Uniform Hazardous Waste Manifest
System
Generators of hazardous wastes; transporters of such wastes;
and operators of treatment, storage, and disposal facilities (TSDFs)
must also comply with the Uniform Hazardous Waste Manifest
System. 177 This System requires the use of a manifest process to
track hazardous waste from its point of origin to its ultimate point
of treatment or disposal (i.e., “cradle to grave”). 178 Transporters
of hazardous waste must also meet requirements established by
the Department of Transportation. 179 For example, regulations
implementing the Hazardous Materials Transportation Act require
(a) labeling, (b) placarding, (c) proper containers for hazardous
materials, and (d) the development of emergency (spill) response
procedures. 180

176

Case, supra note 164, at 150.

177

§ 262.20; Case, supra note 164, at 150.

178

Case, supra note 164, at 150.

179

Id. at 134.

180

Id.

181

40 C.F.R. § 264.1 (2010).

182

Id.

183

See § 264.145; see also Case, supra note 164, at 161.

184

Case, supra note 164, at 170.

185

§ 264.314.

186

Id.

187

Case, supra note 164, at 164-65.

188

§ 264.301; Case, supra note 164, at 164-65.

RCRA also establishes minimum technological standards for
new landfills and surface impoundments. Requirements include:
(a) double liners, (b) a leachate collection and treatment system,
(c) groundwater monitoring, and (d) in general, the use of “Best
Demonstrated Available Technology.” 188

C.4.5. The Universal Waste Rule
In 1995, EPA promulgated regulations to streamline the
management of certain types of commonly occurring hazardous

26

C.5. Protection of Groundwater and Surface Water
Quality by Regulating Toxic Substances: The Toxic
Substance Control Act

wastes.189 These wastes (known as “universal wastes”) included
batteries, certain types of lamps (e.g., containing mercury),
mercury-containing equipment (e.g., thermostats) and certain types
of pesticides. Concluding that the “current RCRA regulations
have been a major impediment to national collection and recycling
campaigns for these wastes,” 190 the Universal Waste Rule
(UWR) 191 was promulgated to “facilitate [their] environmentally
sound collection and increase the proper recycling or treatment” of
such wastes. 192

In 1971, the Council on Environmental Quality (CEQ )
recommended comprehensive legislation to identify and control
chemicals whose manufacture, processing, distribution, use,
and/or disposal was potentially dangerous and not adequately
regulated under other environmental statutes. 195
The result, the Toxic Substances Control Act (TSCA), was
signed into law by President Ford on October 11, 1976. 196

To achieve these goals, the UWR allowed for longer storage
of covered wastes, reduced record keeping requirements and
simplified the procedure for recycling such wastes. Transportation
was facilitated by exempting the transport of wastes included
within the UWR from the manifest requirements discussed above.

Title I of TSCA focuses on the control of toxic substances.
Manufacturers and processors are required to conduct tests of
existing chemicals if (a) the manufacture, distribution, processing,
use or disposal of the chemicals may present an unreasonable
risk of injury to health or the environment; (b) the chemicals are
or will be produced in substantial quantities and the potential
for environmental release or human exposure is substantial or
significant; and (c) existing data are inadequate to predict the
effects of human exposure and environmental releases. 197 The
required testing may be based on risk triggers (chemical toxicity,
etc.), exposure triggers (long-term, low-level exposure) or both. 198
Chemicals known or suspected to be carcinogenic, mutagenic or
teratogenic are to be assigned a higher priority for testing. 199

C.4.6. State Implementation
The EPA encouraged states to assume responsibility for
RCRA’s hazardous waste program in part by providing financial
assistance. 193 At the present time, all but two of the states have
been granted authority to implement the RCRA program. 194

Universal Waste Rule (Hazardous Waste Management System; Modification of the Hazardous Waste Recycling Regulatory Program);
60 Fed. Reg. 25492 (May 11, 1995).

189

190

Id. at 25492.

191

40 C.F.R. Part 273.

192

60 Fed. Reg. at 25492.

193

RCRA § 6947.

It appears that Alaska and Iowa have not been granted authority to implement the RCRA program. See Environmental Protection
Agency, Wastes-Laws & Regulations-RCRA State Authorization: State Authorization Federal Register Notices and Authorization
Activity, http://www.epa.gov/osw/lawsregs/ state/stats/stats_safrn.htm (last visited Sept. 10, 2010).
194

This recommendation was contained in the CEQ report Toxic Substances (1971). Linda Schierow, Congressional Research Services,
Summary of Environmental Laws Adminstered by the EPA, available at http://ncseonline.org/nle/crsreports/briefingbooks/laws/k.
cfm (last visited July 18, 2010).
195

Toxic Substance Control Act (TSCA), Pub. L. No. 94-469, 90 Stat. 2003 (codified as amended at 15 U.S.C. §§ 2601-1692(2006));
Stanley W. Landfair, Toxic Substance Control Ac t, in Environmental Law Handbook 607, 607 (Thomas F.P. Sullivan ed., Government
Institutes 19th ed. 2007).
196

197

TSCA § 2603; Landfair, supra note 196, at 644.

198

Landfair, supra note 196, at 644.

199

See id. at 643.
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C.5.1. The Inventory

C.5.3. Regulatory Controls

The EPA is required to develop and maintain an inventory
of all chemicals, or categories of chemicals, manufactured or
processed in the United States. 200 All chemicals not on the
Inventory are, by definition, “new” and are subject to the PreManufacture Notification requirements. 201

The TSCA requires the EPA to regulate the manufacturing,
processing, distribution, use, and disposal of a chemical if it
will present an unreasonable risk of injury to health or the
environment. 207 This authority allows EPA to: (a) prohibit or
limit the amount of production or distribution of a chemical;
(b) prohibit or limit the production or distribution of a chemical
for a particular use; (c) limit the volume or concentration of
the chemical produced; (d) prohibit or regulate the manner or
method of commercial use; (e) require warning labels and/or
instructions on containers or products; (f) require notification
of the risk of injury to distributors and (to the extent possible)
consumers; (g) require record-keeping by producers; (h) specify
disposal methods; and (i) require replacement or repurchase
of products already distributed. 208 However, the EPA is to
exercise this authority only “to the extent necessary to protect
adequately” against a risk. Furthermore, the EPA is to use
the “least burdensome” regulatory approach, even when
unreasonable risks are being controlled. 209

In 2008, the EPA initiated a phased, multi-year program to
obtain health and safety information from manufacturers and
processors of inorganic, high-production volume (HPV) chemicals.
202
Such information on 2,200 organic chemical HPV chemicals
has already been obtained by the EPA. 203

C.5.2. Pre-Manufacture Notification
With limited exceptions, manufacturers, importers, and
processors of chemicals not listed in the inventory are required to
notify the EPA at least 90 days prior to producing a new chemical
product into the United States. 204\ The EPA then has 45 days to
evaluate the potential risk posed by the new chemical product. 205
If the EPA determines that the new chemical product presents
or will present an unreasonable risk of injury to human health or
the environment, then requirements to protect against such risks
must be promulgated. If data are inadequate to make an informed
judgment, the EPA may prohibit or limit the use of the new
chemical product until sufficient information has been submitted. 206

C.5.4. Imminent Hazards
The TSCA also authorizes the EPA to take emergency action
through federal courts to control a chemical substance or mixture
which presents an imminent and unreasonable risk of serious,
widespread injury to human health or the environment 210

200

TSCA § 2607(b)(1).

201

See id. §2607(b); see also Landfair, supra note 196, at 611.

202

High Production Volume (HPV) Challenge Program, http://www.epa.gov/hpv (last visited Sept. 9, 2010).

203

Id.

204

TSCA § 2604(a)(1)(B).

205

Id. §2604(e)(1)(B).

206

Id. §2604(e)(1)(A).

207

Id. §2605(a).

208

Id.

209

Id.

210

Id. § 2606(b)(1).
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C.6. Protection of Species: The Endangered Species Act

endangered species and threatened species and shall utilize their
authorities in furtherance of the purposes of this chapter.” 214 In
essence, the ESA was intended to protect threatened and endangered
species virtually irrespective of the cost of the protection. 215

Perhaps the best known of the federal species protection
statutes, the Endangered Species Act (ESA) 211 essentially prohibits
any federal agency from taking any action (including destruction of
“critical habitat”) that would jeopardize the continued existence of
a threatened or endangered plant or animal species. As more fully
discussed below, the ESA also prohibits all parties (both public and
private) from undertaking actions that would result in the “taking”
of a threatened or endangered species. 212

C.6.1. “Taking” Endangered Species
With only limited exceptions, Congress prohibited the “taking”
of an “endangered”216 plant or animal species. 217 Fish and Wildlife
Service regulations extending these provisions to “threatened” 218
species were sustained when challenged as a reasonable and
permissible interpretation of the ESA. 219

The purposes of the ESA are “to provide a means whereby the
ecosystems upon which endangered species and threatened species
depend may be conserved, [and] to provide a program for the
conservation of such endangered species and threatened species[.]”
213
In order to achieve these goals, Congress established the policy
that “all Federal departments and agencies shall seek to conserve

211

Concurrent with the determination that a species is endangered
or threatened, the Secretary of the Interior must designate critical
habitat. 220

See generally Endangered Species Act (ESA), Pub. L. No. 93-205, 87 Stat. 884 (codified as amended at 16 U.S.C. §§ 1531-1544

(2006)).
212

ESA § 1538(a)(1).

213

Id. § 1531(b).

214

Id. § 1531(c)(1).

See Tennessee Valley Authority v. Hill, 437 U.S. 153 (1978) (holding that the protection of the endangered snail darter under the
ESA could preclude completion of a water project). 216 Endangered species are defined as “any species which is in danger of extinction
throughout all or a significant portion of its range other than a species of the Class Insecta determined by the Secretary to constitute a pest
whose protection under the provisions of this chapter would present an overwhelming and overriding risk to man.” ESA §1532(6).
215

In relevant part, the ESA provides that “with respect to any endangered species of fish or wildlife listed pursuant to ... this title it is
unlawful for any person subject to the jurisdiction of the United States to ... (B) take any such species within the United States or the
territorial sea of the United States ... or (G) violate any regulation pertaining to such species or to any threatened species of fish or wildlife
listed pursuant to ... this title.” ESA § 1538(a)(1). Furthermore, “with respect to any endangered species of plants listed pursuant to ... this
title, it is unlawful for any person subject to the jurisdiction of the United States to ... (B) remove and reduce to possession any such species
from areas under Federal jurisdiction; maliciously damage or destroy any such species on any such area; or remove, cut, dig up, or damage
or destroy any such species on any other area in knowing violation of any law or regulation of any State or in the course of any violation of
a State criminal trespass law ... or (E) violate any regulation pertaining to such species or to any threatened species of plants listed pursuant
to ... this title….” Id. § 1538(a)(2).
217

Threatened species are defined as “any species which is likely to become an endangered species within the foreseeable future throughout
all or a significant portion of its range.” Id. § 1532(20).
218

Sweet Home Chapter of Communities for a Great Oregon v. Lujan, 806 F. Supp. 279 (D.D.C. 1992), aff ’d sub nom Sweet Home
Chapter of Communities for a Great Oregon v. Babbitt, 1 F.3d 1 (D.C. Cir. 1993), modified, 17 F.3d 1463 (D.C. Cir. 1994), rev’d, 515
U.S. 687 (1995).
219

220

In making a determination regarding the designation of critical habitat, the Secretary
shall designate critical habitat ... on the basis of the best scientific data available and after taking into consideration the economic
impact, and any other relevant impact, of specifying any particular area as critical habitat. The Secretary may exclude any area
from critical habitat if he determines that the benefits of such exclusion outweigh the benefits of specifying such area as part of the
critical habitat, unless he determines, based on the best scientific and commercial data available, that the failure to designate such
29

includes: (a) actions authorized by a federal agency (e.g., through
the issuance of permits or licenses); (b) actions funded by federal
agencies; and (c) actions undertaken by the agency itself. 226

With regard to the “taking” of an endangered or threatened
species, the definition of “take” is noteworthy: “The term ‘take’
means to harass, harm, pursue, hunt, shoot, wound, kill, trap,
capture, or collect, or to attempt to engage in any such conduct.” 221
To conclude that the definition of “take” is quite broad would be
an understatement. Registration of a pesticide by the EPA, for
example, was considered a “taking” since endangered species were
poisoned by the pesticide. 222 Forest management practices of the
Forest Service, which resulted in harm to an endangered species,
constituted a “taking” in Sierra Club v. Lyng. 223

In order to fulfill this requirement, agencies are required
to “use the best scientific and commercial data available.” 227
Agencies are also required to act “in consultation with and with the
assistance of ” the Secretary of the Interior. 228

D. Alternative Strategies:
As an alternative to a regulatory approach, there are a number
of possibilities that could be utilized to address the presence
of PPCPs in water supplies through source control.229 These
possibilities fall generally into six categories: drug design, drug
delivery, drug marketing, drug dispensing, drug disposal/recycling,
and drug alternatives.230 While these categories focus primarily on
pharmaceuticals, they apply equally to personal care products and

C.6.2. Interagency Coordination
Federal agencies are required to insure that agency actions are
not likely to jeopardize the continued existence of a threatened or
endangered species. 224 Such agencies are also required to insure
that agency actions do not result in the destruction or adverse
modification of critical habitat. 225 In this context, “agency action”

area as critical habitat will result in the extinction of the species concerned.
ESA § 1533(b)(2).
221

Id. §1532(19).

222

Defenders of Wildlife v. Administrator, EPA, 882 F.2d 1294 (8th Cir. 1989).

223

Sierra Club v. Lyng, 694 F. Supp. 1260 (E.D. Tex. 1988), aff ’d in part, vacated in part, 926 F.2d 429 (5th Cir. 1991).

224

ESA § 1536(a)(2).

225

Id.

226

Id.

227

Id.

228

Id.

The need for source control has been stressed in a number of studies. See, e.g., the recommendations of a 2008 study by the School of
Public Health and Health Services at The George Washington University included:

229

An emphasis on controlling the discharge of contaminated water at the source, rather than treatment at the point of use. This
would be safer for the environment, while reducing the burden on downstream drinking water treatment plants.
Rapid Public Health Policy Response Project, supra note 26, at 6 (citing U.S. Environmental Protection Agency, Source Water
Protection). See also Keith J. Jones, Endocrine Disruptors and Risk Assessment: Potential for a Big Mistake, 17 Villanoval
Environmental Law Journal 357, 386 (2006) (“It might be more feasible to ban the use of an endocrine disruptor or otherwise prevent
it from reaching source water (e.g., source water protection programs) rather than try to remove it from drinking water.”).
The structure of this section and the concepts described herein are based on Christian G. Daughton, Cradle-to-Cradle Stewardship of
Drugs for Minimizing Their Environmental Disposition While Promoting Human Health. II. Drug Disposal, Waste Reduction, and Future
Directions, 111 Environmental Health Perspectives 775 (2003) [hereinafter Daughton, Drug Disposal, Waste Reduction, and Future
Directions]. See also the section on “source water protection” in Snyder et al., supra note 47, at 34.

230

30

In this context, it should be noted that the U.S. Food and Drug
Administration mandates environmental risk assessments for new
pharmaceuticals having a predicted environmental concentration of
more than 1 μg/L. 234

the full array of PPCPs previously identified in footnote 6.231

D.1. Drug Design
The environmental impacts of drug use, such as the excretion of
PPCPs in both human and animal wastes, should be considered as
new drugs are being designed or formulated. While maintaining or
improving therapeutic efficacy, the chemical structure, properties,
and formulation (combinations of active and inactive ingredients)
of new drugs could focus on “maximizing their susceptibility to
biodegradation, photolysis, or other physicochemical alterations to
yield innocuous end products.” 232 The need for such an approach
was described by Wennmalm and Gunnarsson:

It would be possible to design drugs to improve the physiologic
sorption characteristics of the drug. This would result in a
reduction in the amount of the drug ultimately excreted. This
possibility is “being pursued on many fronts[.]” 235
Daughton notes that the “advancing ‘omnics’ revolution” 236
could lead to the design of drugs that specifically target certain
groups of patients. This could have the effect of reducing the
use of drugs having similar therapeutic effects by the general
population. 237 If use of drugs resulting in the excretion of PPCPs
by the general population was reduced, then the quantity of PPCPs
entering water supplies would also be reduced.

[I]t appears urgent that future drugs not be persistent.
Presently, several frequently used drugs have half-lives
in surface water exceeding one year or more. Residues
of such drugs may reach concentrations in surface or
ground water near urban areas of 100 nanograms/litre
or more before a kinetic balance between supply of new
drug residues from sewage treatment plant effluents and
biodegradation in the aquatic medium has been reached.
Such high concentrations are not readily eliminated in
processes aimed at purifying the water to be drinkable.
Thus, significant concentrations of bioactive drug residues
may appear in drinking water.233

Other drug design possibilities could include the development
of drugs that maintain their therapeutic effectiveness despite
substantially reduced dosage levels 238 as well as the development of
“smart” drugs that “better emulate the nonanthropocentric, native
chemistries of natural products.” 239

231

See supra note 6.

232

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 230, at 765.

Wennmalm & Gunnarsson, supra note 41, at 295-296 (citing Ettore Zuccato et al., Environmental loads and detection of pharmaceuticals
in Italy, in Pharmaceuticals in the Environment 23-24 (K. Kümmerer ed., Springer Verlag 2001)).
233

234

Snyder et al., supra note 47, at 34.

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 230, at 765 (citing Joe Alper, Breaching membranes,
296 SCIENCE 838 (2002)) (regarding the creation of in situ synthetic transporters as well as work by XenoPort, Inc. of Santa Clara,
California regarding “better drug design to accommodate existing membrane transporters[.]”).

235

This would include genomics (the study of genes and their functions), proteomics (the study of proteins and their functions), glycomics
(study of the structure and function of sugars and saccharides) and metabolomics (the study of metabolites and their functions). See
generally Cambridge Healthtech Institute, -Omes and -omics Glossary & Taxonomy: Evolving Terminology for Emerging Technologies,
http://www.genomicglossaries.com/content/omes.asp (last visited Mar. 1, 2011).
236

237

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 230, at 765.

238

Id. at 766.

239

Id.
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D.2. Drug Delivery

The same result could be achieved through more precise
formulation and dosing of drugs. 245 Related to this would
be “individualization of therapy,” which would require drug
manufacturers to “provide the medical community with more easily
implementable information (and requisite unit doses) to tailor drug
dosages for the individual.” 246

The first step in the drug delivery system identified by
Daughton as playing a role vis-àvis PPCPs in water supplies is
the prescribing of drugs. Both physicians and patients need to be
better informed of the consequences of using specific drugs, 240
particularly both the “medical and environmental consequences of
overprescribing medications.”241

The development of alternative drug delivery mechanisms is
another suggested means of improving the efficiency of drug use.
This could include “better targeted delivery routes (e.g., expanding
the utility of pulmonary and transdermal/mucosal delivery),
mechanisms of release (e.g., rapid-dissolving formulations,
controlled release), and mechanisms for delivery of drugs to the
target (e.g., antibody-linked drugs; in situ implants).” 247

Numerous studies have shown that “the therapeutically
effective dose for many drugs can be significantly lower than
that initially recommended by the manufacturer.” 242 In fact,
Cunningham, et al., have noted, “[t]he preferred safety profile for
human pharmaceuticals is that the desired therapeutic response is
the lowest effect observed (i.e., at the lowest dose).” 243 With regard
to drugs whose use results in the excretion of PPCPs, lowering
the dosage to the therapeutically effective level, rather than the
level recommended by the manufacturer, could have the result of
reducing the quantity of PPCPs entering water supplies. 244

With regard to the delivery of drugs, the role of patient
education cannot be overstated. As noted by Daughton, it is
quite common for patients to “fail to finish their courses of
medication[.]” 248 As a result, unused (and perhaps outdated) drugs
accumulate and eventually require disposal. If patients completed

Wennmalm and Gunnarsson describe such an approach in Sweden as well as actions taken by the Stockholm County Council to
implement it:

240

Despite the fact that pharmaceuticals may have adverse environmental effects, no information on such effects is easily available to
prescribing doctors. We have developed a model for easy but accurate evaluation of the environmental effects of drugs, aimed at
helping doctors to make an environmentally-conscious selection between medicallyequivalent drugs with different environmental
impacts. Health care professionals have expressed much interest in the classification system and the Stockholm County
Council has decided that the environmental score of each pharmaceutical obtained in the classification shall be one variable for
consideration when its list of recommended pharmaceuticals is revised.
Wennmalm, & Gunnarsson, supra note 41, at 294-295.
241

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 232, at 766.

242

Id. at 767.

243

Cunningham, Binks, & Olson, supra note 41, at 43.

244

Id.:
For a given use rate by the population, only low production volumes are needed for potent pharmaceuticals. For the same
population use rate, a high therapeutic dose requires more production. So, the total amount of an API [active pharmaceutical
ingredient] entering the environment is generally inversely correlated to its potency.

Id. at 44.
245

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 230, at 767.

246

Daughton notes that “individualization of therapy” is particularly relevant with regard to long-term maintenance drugs. Id.

247

Id. (citing Mona Mort, Multiple Modes of Drug Delivery,” 3 Modern Drug Discovery 30 (2000)).

248

Id. at 768 (citing Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note 230).
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courses of medication as prescribed, the quantity of drugs
inappropriately disposed of would be reduced. This could reduce
the quantity of PPCPs entering water supplies.

This quantity could also be reduced if improved packaging
extended the shelf-life of drugs. 254

253

Finally, the role of drug advertising must be considered. Such
advertising substantially influences consumer decisions regarding
the use of both over-the-counter (nonprescription) and prescription
drugs. Different types of advertising may also influence the
medical community. Because of this, Daughton argues that such
advertising should “include information for the public regarding
the proper disposition of unused products and the imperative for
environmental stewardship.”255

Of equal importance is education of the medical community
regarding both appropriate dosages of specific drugs and
appropriate disposal mechanisms. Daughton advocates the use of
continuing education programs involving both the medicine and
environmental science to teach the importance of “cradle-to-cradle
stewardship” of medications. 249

D.3. Drug Marketing

D.4. Drug Dispensing

As noted above, patient education is a critical factor. The
importance of the role of drug marketing in educating both
the patient and the public cannot be overstated. For example,
Daughton notes that the packaging of both over-the-counter
(nonprescription) and prescription drugs in the United States does
not provide guidance for the disposal of any unused portion of
the medication. 250 Guidance may also be missing regarding the
ingestion of different drugs having the same mechanism of action
or the same drug from different sources, both of which may result
in a cumulative dose in excess of therapeutic requirements. 251 This
problem may be exacerbated by different drugs having a similar
name or appearance. 252

There are any number of means by which both legal and illegal
drugs are dispensed. Sale of drugs via the Internet, for example,
will “undoubtedly [lead] to overdispensing and dispensing without
a prescription[,]” which could have the effect of contributing to the
overall environmental exposure burden caused by such drug use.256
This is particularly true with regard to the distribution of blackmarket and counterfeit drugs, some 25% of which are sold via the
Internet.257 In addition to potential health benefits, reducing the
quantity of such drugs sold online would also reduce the quantity
of such drugs entering the environment either through excretion or
disposal.

With regard to the disposal of drugs, both the size and
integrity of drug packaging may play a role. Daughton notes, for
example, that a broader selection of package sizes could result in
a reduction in the quantity of drugs that are ultimately discarded.

With regard to the disposal of drugs, a number of issues relate
to expiration dates, after which drugs are no longer considered
effective. Daughton notes that expiration dates should be based on
actual, empirical data regarding stability duration rather than on

249

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 230, at 768.

250

Id.

“This multiple-exposure pathway scenario is especially problematic when patients are prescribed medications by multiple physicians; for
patients with multiple health care providers, poor communication can also lead to represcribing of medication that has already been shown
for the patient to be nonefficacious.” Id.

251

Id. at 768-769 (citing Committee on Quality of Health Care in America, Institute of Medicine, To Err is Human: Building a Safer
Health System (Linda T. Kohn, Janet M. Corrigan, & Molla S. Donaldson eds., National Academy Press 2000)). “Although these
problems can jeopardize patient safety, they also lead to unnecessary (and inappropriate) use of drugs and their eventual discharge to the
environment, as well as to the purchase of medications that might not have been made by a betterinformed consumer.” Id. at 769.
252

253

Id. at 769.

254

Id.

255

Id.

256

Id. (citing U.S. Food and Drug Administration, Buying Medicines and Medical Products Online (2002)).

Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 230, at 769 (citing Cyveillance, Cyveillance Partners with
Biocode to Serve Pharmaceutical Industry [press release] (2001)).

257

33

the recommendations of specific drug manufacturers.258

the sale and use of both over-the-counter (nonprescription) and
prescription drugs. Daughton concludes that such a database
“would be extremely useful for predicting the actual quantities
of drugs that could be entering the environment (by using
pharmacokinetic models based on ADME/Tox – adsorption,
distribution, metabolism, excretion, and toxicity).” 262

The need to dispose of unwanted drugs could also be reduced
if more disciplined dispensing and inventory control protocols were
developed. Both pharmacies and consumers could be encouraged
to minimize their drug inventories in order to minimize the
quantity of unwanted or unneeded drugs needing disposal. 259 For
example, the need to dispose of specific drugs would be reduced
if the quantity either purchased or prescribed could be utilized
completely prior to the expiration date of the drug. The disposal
need could also be reduced if “[r]easonable, minimal quantities of
medication could be purchased or prescribed until the effects of the
medication and its therapeutic effectiveness are understood by both
the physician and patient.” 260

D.5. Drug Disposal/Recycling
The need for appropriate disposal or recycling of pharmaceuticals
has been noted repeatedly. 263 A number of suggestions have been
offered to encourage such disposal or recycling programs. Daughton,
for example, has suggested that an appropriate incentive for drug
companies to implement drug disposal/recycling programs “would
be to offer patent extensions to companies that formulate vibrant,
comprehensive stewardship programs tailored for each particular
drug.” 264 Daughton has also suggested that the role of “reverse
distributors” currently being used by pharmacies in the United States
for the return of unsold or expired drugs be expanded “into a larger,
comprehensive disposal/recycling program, one that accommodates
the consumer sector.” 265 Such an expansion might also include drug

Daughton makes two additional points regarding drug
dispensing vis-à-vis PPCPs in water supplies. First, the use
of drugs for purposes not originally intended requires both
vigilance and ongoing review, particularly if such use results
in the introduction of PPCPs into water supplies. 261 Second,
a nationwide database of drug sales is needed. This database,
which should be publically accessible, would compile and track

“Scientifically sound protocols need to be implemented for the public sector to define, determine, predict, and/or monitor actual
expiration periods for both factory-sealed and unsealed drugs.” Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note
230 at 770.

258

259

Id.

260

Id.

For example, “[t]he long-running debates regarding the use of subtherapeutic antibiotics and of anabolic steroids in animal feed have
resulted in a number of actions in certain countries to reduce or abolish their use.” Id. at 771.

261

Id. (citing Christian G. Daughton, U.S. Environmental Protection Agency, Factors Complicating Prediction of Drug Elimination from
the Body (2002)).
262

263

See, e.g., TDC Environmental, supra note 49, at 2; Christenson, supra note 172, at 164-166 (reviewing programs in Arizona, Arkansas

and Wisconsin).
264

Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note 230, at 776.

265

Id. See also TDC Environmental, supra note 49:
U.S. EPA has authorized reverse distribution of pharmaceuticals without hazardous waste management permits. The U.S. EPA
authorization specifically requires the returns industry not to be used as a “waste management system” (U.S. EPA, 1981; U.S.
EPA, 1991). Any items that are inherently “waste-like” (like a broken container or contaminated prescription) cannot be shipped
as products to a reverse distributor.

TDC Environmental, supra note 49, at 4-5 (citing Letter from Alan S. Corson, Chief, Waste Characterization Branch, Hazardous and
Industrial Waste Division, U.S. EPA, to Steven Wittmer, Merck, Sharp & Dohme (May 13, 1981), available at http://yosemite.epa.gov/
OSW/rcra.nsf/Documents/F3001B817EF4265885256611005156D2; Letter from Sylvia K. Lowrance, Director, Office of Solid Waste,
U.S. EPA, to Mark J. Schulz, Browning-Ferris Industries (May 16, 1991) available at http://yosemite.epa.gov/OSW/rcra.nsf/Documen
ts/354FE6A290ED95E1852565DA006F04A1). Accord Christenson, supra note 172, at 165-166. However, it should be noted that any
consumer “reverse distribution” program would have to comply with the privacy requirements of the Health Insurance Portability and
Accountability Act (HIPAA), 42 U.S.C. §201, et seq.. TDC Environmental, supra note 49, at 6.
34

samples given to physicians because the “distributors of physician
samples often instruct physicians to dispose of outdated samples to
the sewage system.” 266

ensure that pharmaceuticals provided to patients are pure
and safe. Once a drug has left the control of a pharmacy,
its storage, handling, and condition are uncertain –
and therefore it cannot be assured to be pure and safe.
Because there is no viable reuse for unwanted residential
pharmaceuticals, they are – by definition – waste.269

Minimization of waste flows into the environment should have
the effect of reducing the presence of PPCPs in water supplies.
One approach could be re-engineered toilets to separate liquid and
solid wastes. This could have the effect of both minimizing waste
flows and reducing water supply requirements. 267

Development of water recycling systems that allow wastewater to
be upgraded for both potable and non-potable uses provides another
approach to minimization of waste flows. 270 As Daughton notes:
“By use of advanced water treatment technology such as reverse
osmosis, nearly complete removal of all PPCPs can be achieved.”
271
This is an issue of particular concern in arid regions, particularly
the southwestern United States, where limited water supplies and
growing populations virtually mandate the reuse of water. 272

Another approach could be “drug mining” (i.e., recovery of
highly toxic drugs from excreta and other hospital wastes).268
However, with only limited exceptions, any subsequent use of
reclaimed or recycled drugs is prohibited:
Once prescribed and given to patients, pharmaceuticals
cannot be reused. State [California] and Federal law
require pharmacists and pharmaceutical manufacturers to

266

Improvements to wastewater collection 273 and treatment 274
systems are closely associated with the development of water

Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note 230, at 776.

Id. (citing Tove A. Larsen et al., Re-engineering the Toilet for Sustainable Wastewater Management, 35 Environmental Science
& Technology 192A (2001); Novaquatis, EAWAG (Swiss Federal Institute for Environmental Science and Technology), Innovative
Management of Anthropogenic Nutrients in Urban Water Management and Agriculture (2002); R. Otterpohl, Options
for Alternative Types of Sewerage and Treatment Systems Directed to Improvement of the Overall Performance, 45 Water Science &
Technology 149 (2002))
267

Id. at 776 (referring to a prototype of such a system developed by Pharmaceuticals.org). See Pharmaceuticals.org, Pharmaceuticals from
Human System to Human System, http://www.toilets.com/pharmaceuticals.htm (last visited March 1, 2011).

268

269

TDC Environmental, supra note 49, at 8.

Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note 232, at 776 (citing Jorge E. Drewes & Laurence S. Shore,
Concerns About Pharmaceuticals in Water Reuse, Groundwater Recharge, and Animal Waste, in Pharmaceuticals and Personal Care
270

Products in the Environment: Scientific and Regulatory Issues 206 (Christian G. Daughton & Tammy L. Jones- Lepp eds.,
American Chemical Society 2002); Lindsey A. Greene, Controversy Swirls Around Toilet-to- Tap Project, 108 Environmental Health
Perspectives A447 (2000)).

Id. It should be noted, however, that “all the solutes removed by reverse osmosis are concentrated inthe rejected “brine” – a waste stream
that must be disposed itself.” Id.

271

272

Snyder et al., supra note 47, at 34.

Collection system improvements need to address both combined sewer overflows and urban streamstormflows as these are “significant
contributors of OWCs [organic water compounds] to receiving waters[.]” Phillips & Chalmers, supra note 86, at 56.

273

This in turn indicates that efforts to decrease the amounts of OWCs entering large receiving waters need to identify and treat
waters that bypass normal wastewatertreatment processes. Future evaluations of the annual contributions from these sources will
require sampling of WWTP effluents, CSO effluents, and urban streams under differing seasons and flow conditions.

Id.
With regard to the control of PPCPs in water supplies, development of advanced wastewater treatment systems “could have the greatest
potential benefit, as it would remove not only intentionally flushed drugs but also drugs that pass through the body naturally.” Christenson,
supra note 172, at 159 (citing George J. Mannina, Jr., Medicines and the Environment: Legal and Regulatory Storms Ahead?, 21 Legal
Backgrounder, no. 11, 2 (March 26, 2006)).
274

35

recycling systems. Advanced wastewater treatment systems using
reverse osmosis have the capability to remove PPCPs through a
physical separation process. 275 Utilization of granular activated
charcoal systems, as well as ozonation, has been effective in
removing antibiotics from wastewater. 276 Engineered wetlands
and groundwater infiltration basins have been suggested as
mechanisms to attenuate PPCPs 277 as has phytoremediation. 278
At a more basic level, Daughton recommends both that “[s]traightpiping of sewage to surface waters ... continue to be identified
and eliminated” 279 and that “[p]rivies and septic systems ... be
converted to municipal systems when feasible.” 280

“pose problems with respect to groundwater pollution if they have
not been properly engineered and sited with local hydrogeologic
processes in mind,” 283 but the presence of PPCPs in the bodies of
the deceased “could be expected to be extensive as a result of longterm medication and heroic treatment measures.” 284
Once again, the role of public education needs to be stressed,
this time in the context of drug disposal/recycling. Daughton
emphasizes the importance of public outreach programs:
A well-designed, concerted public outreach program
for communicating the issues associated with PPCPs as
environmental pollutants could accomplish dual aims:
(a) enhance the public’s appreciation and understanding
of a wide range of principles associated with
environmental science, and (b) increase the public’s sense
of environmental responsibility by showing how their
actions as individuals collectively contribute to the burden
of PPCPs in the environment, how PPCPs can possibly
affect environmental processes (e.g., aquatic biota), and
the collateral advantages (human health and economic)
accrued by conscientious/responsible disposal and use of
PPCPs.285

With regard to reducing the environmental burden caused by
both the legal and illegal disposal of drugs, Daughton notes the need
to revise state laws that either (a) restrict the donation of prescription
drugs to charity (e.g., Oklahoma) 281 or (b) restrict or limit the
authority of pharmacies to accept returns of unused drugs. 282
The complexity of issues relating to PPCPs in water supplies
is illustrated by Daughton’s observation that funeral practices
need to be environmentally sound. Not only can burial practices

Sedlak and Pinkston, supra note 15, at 56. Accord Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25; Heberer et al.,
Removal of Pharmaceutical Residues, supra note 85, at 28.
275

Huang et al., supra note 25, at 37. Accord Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25, (citing Marc M. Huber
et al., Oxidation of pharmaceuticals during ozonation and advanced oxidation processes, 36 Environmental Science & Technology 1202
(2003)).
276

277

Sedlak and Pinkston, supra note 15, at 65.

278

N. Gujarathi & J. Linden, Potential for Phytoremediation of Antibiotic-Contaminated Water, 24 Agronomy News 9 (2004).

Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note 230, at 776 (citing Sue Anne Pressley, North Carolina
Effort Seeks to Wipe Out Outhouses, Washington Post, Apr. 25, 1999, at A3).
279

280

Id.

Id. at 776-77 (citing College of Osteopathic Medicine, Oklahoma State University, Prescription Medicines and Nursing Home:
A Problem ... A Solution, Health and Medicine Issue Paper (2000); and College of Osteopathic Medicine, Oklahoma State
University, Prescription Medicines and Nursing Homes: Laws - Letters - Reports - Policies. An Issue Paper Resource
Supplement (2000)).
281

282

Id. at 777.

283

Id. (citing Croukamp, Environmental-, Engineering- and Marine-Geoscience Division, Council forGeoscience, Cemetery Site

Investigations (1999)).
284

Id.

285

Id.
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D.6. Drug Alternatives

E. Case Study Based on Project 2 Results:

A condition precedent to the release of PPCPs into water
supplies is the use of PPCPs. It is both obvious and frequently
overlooked that a reduction in the use of PPCPs would also reduce
the quantity of PPCPs released into water supplies. Daughton notes,
for example, that nutrition and health maintenance programs, by
reducing the incidence of diseases requiring treatment, also reduce
the release of PPCPs associated with such treatment. 286

The Project 2 research focused on the presence of PPCPs
in soil and groundwater in West Texas.289 As more thoroughly
discussed below, this research focused on four inter-related research
topics: (a) the sorption of PPCPs in different types of soils; (b)
the degradation of PPCPs in soil under aerobic and anaerobic
conditions; (c) the degradation of PPCPs in soil with high water
content; and (d) the presence of PPCPs in a wastewater treatment
plant and in both soil and groundwater at sites to which treated
wastewater had been applied.290

When treatment is required, use of alternative drugs (i.e.,
drugs not containing PPCPs) should be considered. As an
example, Daughton notes that there is a “wide range of medical
uses of probiotics” (beneficial, endogenous microflora). 287 Such
“bacteriotherapy” may achieve the same results as the use of drugs
containing PPCPs but without the attendant execration or disposal
problems. 288

As noted in Section II, the research is relevant to the issue
of PPCPs in water supplies because of disposal methods used by
wastewater treatment plants for both solid and liquid wastes.291
Solid wastes (sludge or biosolids) and liquid wastes are applied to

Id. In terms of reducing the use of PPCPs, Daughton suggest that “more research could be directed at reducing (or eliminating)
drug dosages via the use of placebos.” Id. (citing Damaris Christensen, Medicinal Mimicry: Sometimes, Placebos Work – But How? 159
Science News 74 (2001); Andrew F. Leuchter et al., Changes in Brain Function of Depressed Subjects During Treatment with Placebo, 159

286

American Journal of Psychiatry 122 (2002)).
287

Id. (citing Bob Beale, Probiotics: Their Tiny Worlds are Under Scrutiny, 16 Scientist 20 (2002)).

As an example, Daughton notes that probiotics “have long been used and studied for the protection of the gut” because of the capability
of probiotics to block pathogen adhesion. Id. (citing Indu Pal Kaur et al., Probiotics: Potential Pharmaceutical Applications, 15 European
Journal of Pharmaceutical Sciences 1 (2002)).
288

All of the sites involved in this research had been subjected to disposal of treated waste water effluent through land application by the
City of Lubbock’s municipal waste water treatment facility, in some cases, for the past 70 years. These sites were ideal for this type of study,
in part, because there are very few discharges of treated waste water effluent “upstream” of the City of Lubbock’s chief sources of municipal
fresh water, which include Lake Meredith on the Canadian River and the Ogallala Aquifer. The effects of being located downstream of a
waste water treatment are discussed supra note 80, and accompanying text.

289

Monteiro & Boxall express concern “over the potential impacts of biosolid-associated pharmaceuticals on terrestrial systems and
associated groundwaters and surface waters[,]” Monteiro & Boxall, supra note 53, at 2546, noting:
290

• “In biosolids destined for land application, a number of pharmaceuticals and personal care products have been detected.” Id.
(citing Chad A. Kinney et al., Survey ofOorganic Wastewater Contaminants in Biosolids Destined for Land Application, 40
Environmental Science & Technology 7207 (2006); Chris D. Metcalfe et al., Distribution of Acidic and Neutral Drugs
in Surface Waters Near Sewage Treatment Plants in the Lower Great Lakes, Canada, 22 Environmental Toxicology &
Chemistry 2881 (2003)).
• “Other studies have detected pharmaceuticals in biosolid-amended soils.” Id. (citing Chad A. Kinney et al., Bioaccumulation

of Pharmaceuticals and Other Anthropogenic Waste Indicators in Earthworms from Agricultural Soil Amended with Biosolid
or Swine Manure, 42 Environmental Science & Technology 1863 (2008); Eva M. Golet et al., Determination of
Fluoroquinolone Antibacterial Agents in Sewage Sludge and Sludge-treated Soil Using Accelerated Solvent Extraction Followed by
Solid-phase Extraction, 64 Analytical Chemistry (2002)).
As noted previously, this is an increasing concern in areas of the world where reclaimed wastewater is being used for irrigation. Kinney
et al. addressed this issue:

291

As the range of uses and number of demands for potable water has increased, alternatives to using drinking water for agricultural
and landscape irrigation have been of increasing interest. Reclaimed water is gaining use for irrigation; however, little is known
37

lands that have been designated as application sites. The waste
products then are degraded by natural processes.

collected in Terry County, Texas and a silt loam collected in
Harlan County, Nebraska. As a control, laboratory sand was used.

An emerging concern is the sufficiency of natural processes
to degrade PPCPs before they migrate through the soils into
groundwater or bioaccumulate in species inhabiting the soil
environment.292 With regard to the effects of bioaccumulation of
PPCPs, specifically triclosan (TCS), Lozano et al. concluded:

The results of the study indicated that sorption capacity was a
function of the organic carbon content of the soils. The silt loam,
having the highest organic carbon content, also had the greatest
sorption capacity. The laboratory sand, having the lowest organic
carbon content, also had the least sorption capacity.

Since TCS is a bacteriostat, there is a real potential that
concentrations in soils resulting from biosolid applications
might affect bacterial ecology of these systems. Especially
since the ecological balance and competitive advantages of
the multiple species inhabiting any soil environment are
very complex and any small advantage one microbe might
achieve due to exposure to these known bacteriostat could
be amplified under these conditions.293

In terms of the sample PPCPs, estrone, 17-estradiol,
17-ethynylestradiol, and triclosan had a strong tendency to sorb
to the test soils. Once sorbed, the tendency of these substances
to desorb and migrate into groundwater was minimal. The same
could not be said for estriol and caffeine, both of which had the
potential to migrate into groundwater if soil leaching occurred.

E.2. Microbially Mediated Degradation of
Common Pharmaceuticals and Personal Care
Products in Soil Under Aerobic and Anaerobic
Conditions298

E.1. Sorption of Estrogens, Triclosan, and Caffeine
in a Sandy Loam and a Silt Loam Soil 294
Simply stated, sorption is the process by which one substance
attaches to or holds another substance. Karnjanapiboonwong et
al.’s research focused on the sorption of sample PPCPs in different
types of soil.

The City of Lubbock, Texas, disposes of treated effluent from
its municipal wastewater treatment plant by applying it to lands
designated a land application site. This site received an average of
13 million gallons per day of effluent, which was applied to the
land using 31 center pivot sprinklers. Soil samples were collected
from areas irrigated by the sprinklers (exposed soils) and from
adjacent areas that had not been exposed to the treated effluent
(unexposed soils).

The sample PPCPs were estrogens (estrone, 17-estradiol,
estriol and 17- ethynylestradiol) 295 triclosan,296 and caffeine.297 The
PPCPs were contained in biosolids produced from a municipal
wastewater treatment plant. The soil types were a sandy loam

about the potential for contamination of surface water and groundwater by use of this source.
Kinney et al., supra note 26 (citing H. Bouwer et al., Integrating Water Management and Re-use: Causes for Concern? 1-2 Water Quality
International 19 (1999)).
292

Id. (organic wastewater contaminants “might accumulate in soil if introduced through irrigation water”).

293

Lozano et al., supra note 87, at 764.

Adcharee Karnjanapiboonwong et al., Sorption of Estrogens, Triclosan, and Caffeine in a Sandy Loam and a Silt Loam Soil, 10 Journal
of Soils and Sediments 1300 (2010).

294

Estrone, 17ß-estradiol and estriol are naturally-occurring estrogens while 17 -ethynylestradiol is a synthetic estrogen commonly used
in birth control pills. Research has indicated that 17 -ethynylestradiol may disrupt the reproductive capabilities of a number of different
species. Id.

295

Triclosan is an antibacterial agent found in a number of consumer products such as soaps and cleaning supplies. Concern has been
expressed that the presence of triclosan in water supplies may be causing bacteria to develop immunities to antibiotics. It has also been
suggested that triclosan in combination with chlorine may form chloroform, a known carcinogen. Id.
296

297

The presence of caffeine usually indicates the presence of human waste products as no other animal consumes or excretes caffeine. Id.

Deborah L. Carr, Audra N. Morse, John C. Zak & Todd A. Anderson, Biological Degradation of Common Pharmaceuticals and Personal
Care Products in Soils with High Water Content, Water, Air & Soil Pollution (forthcoming).

298

38

The researchers identified numerous PPCPs in the treated
effluent, including estrogens (estrone, 17-estradiol, estriol and
17-ethynylestradiol), triclosan, ibuprofen, 299 and ciprofloxacin.300
The rate of degradation of these PPCPs was calculated under
aerobic and anaerobic conditions for PPCPs introduced into both
exposed and unexposed soils.

substance previously (as was the case at the land application site) as
compared to soils that had not been previously exposed.

E.4. Occurrence of PPCPs at a Wastewater
Treatment Plant and in Soil and Groundwater at a
Land Application Site 303

The degradation rates for specific substances varied with soil
type and with aerobic/anaerobic condition. The most notable
finding was that, under anaerobic conditions, the degradation rate
increased in exposed soils.

The aforementioned Lubbock, Texas wastewater treatment
plant and land application site were also involved in this component
of the research. Water and sludge samples were obtained from the
wastewater treatment plant with soil and groundwater samples
being obtained from the land application site. As noted above, the
treated effluent was distributed through the use of 31 center pivot
irrigation sprinklers. Samples were also obtained from adjacent
areas that were not irrigated with this effluent.

E.3. Biological Degradation of Common
Pharmaceuticals and Personal Care Products in
Soils with High Water Content301
This element of this case study addressed the movement of
water through soils. As noted by the researchers, soil texture affects
the movement of water, with more finely textured soils holding
water in pore space. The researchers also noted that oxygen
availability is limited in submerged soils and that this slows the
process of biological decay.

The target PPCPs, all of which were present in the
wastewater effluent,304 were estrogens (estrone, 17ß-estradiol,
estriol and 17ά-ethynylestradiol), triclosan, caffeine, ibuprofen
and ciprofloxacin. The research question was whether these
PPCPs biodegraded, accumulated in the soils, or migrated into
groundwater.

Soil samples were collected from the aforementioned site used
by the City of Lubbock, Texas for land disposal of treated effluent.
This effluent contained multiple PPCPs, including estrogens
(estrone, 17 -estradiol, estriol and 17 -ethynylestradiol), triclosan,
and ibprofen. The research focused on the extent to which
biological decay of these PPCPs was affected by the moisture
content of the soils at the land application site.

The research results are illustrative of the difficulties inherent
in the management of PPCPs. The presence of PPCPs in both the
sludge and effluent from the wastewater treatment plant varied over
time. PPCPs may sorb to the wastewater treatment plant sludge,
which could complicate land disposal of such sludge.
With regard to the land application site, PPCPs were detected
within the areas receiving effluent from the center pivot sprinklers
as well as from adjacent areas that had not been irrigated but
apparently were receiving runoff from the areas that had been
irrigated. The presence of PPCPs in both areas varied over time.
This variability was most likely a function of the variable presence
of PPCPs in the effluent from the wastewater treatment plant.

In general, the research demonstrated that the time needed
for biological decay to occur increased in soils with high water
content.302 The extent of this increase varied with both the specific
substance and the duration of the high water content. Another
variable was the extent to which the soils had been exposed to the

Ibprofen is a non-steroidal anti-inflammatory drug that is marketed for pain relief under a variety of different names (e.g., Motrin,
Advil, etc.).
299

300

Ciprofloxacin is a common antibiotic that is sold worldwide for both human and veterinary use.

Deborah L. Carr et al., Microbially Mediated Degradation of Common Pharmaceuticals and Personal Care Products in Soil Under Aerobic
and Anaerobic Conditions, 216 Water, Air & Soil Pollution 633 (2011).

301

302

The only exception was ibuprofen which appeared to demonstrate increased degradation in soils with high water content.

Adcharee Karnjanapiboonwong et al., Occurrence of PPCPs at a Wastewater Treatment Plant and in Soil and Groundwater at a Land
Application Site, 216 Water, Air, & Soil Pollution 257 (2010) [hereinafter Karnjanapiboonwong, Occurrence of PPCPs]..
303

Interestingly, 17ᾰ-ethynylestradiol was not detected in the sludge from the wastewater treatment plant. All the other target PPCPs were
detected. Id.

304

39

The presence of PPCPs also varied with the depth of the
soil from which samples were taken. This led the researchers to
conclude: “Any trend in target PPCP concentrations with soil
depth was difficult to discern and is likely due to the various
biodegradation rates of PPCPs with soil depth; degradation of
PPCPs can be affected by environmental conditions such as
temperature, pH, moisture content, organic carbon, presence of
specific microorganisms, and presence/absence of oxygen.”305

evaluating the potential long-term effects of PPCPs from
contamination of soil and eventually groundwater if that
water is to be used for drinking-water purposes.306

E.5. Conclusions from the Case Study

Of all of the PPCPs included in the study, only ibuprofen
was not detected in the groundwater samples. This was true
irrespective of whether the groundwater samples were drawn from
the areas irrigated with the wastewater effluent or from adjacent
areas that had not been irrigated. The research concluded:

The research results summarized above relate to a series of
studies involving the presence of a fairly limited number of PPCPs
at a relatively small number of sites. With one exception (soil
samples from Harlan County, Nebraska), all of the sampling was
done at the Lubbock, Texas wastewater treatment plant, the land
application site for effluent from the plant, or lands adjacent to the
land application site.

PPCPs in the effluent from a wastewater treatment
plant can eventually move to groundwater via land
application of the effluent. However, PPCPs detected in
groundwater at the study site were at low concentrations
which are not likely to represent a concern and indicate
that the land application process is reasonably effective at
PPCP removal[.] … Our findings may be important for

Nonetheless, a significant amount of variability was noted.
Degradation of PPCPs was seen to be affected by: (a) soil type and
organic content; (b) soil moisture content (including variation in
rainfall); (c) soil oxygen content; and (d) prior exposure to PPCPs.
As noted above with regard to the presence of PPCPs in soils,
additional variables could include temperature, acidity/alkalinity
and the presence of specific microorganisms.307

305

Id. (citing Monteiro,supra note 56; Alistair B.A. Boxall, Fate and Transport of Veterinary Medicines in the Soil Environment, in Fate

of Pharmaceuticals in the Environment and in Water Treatment Systems (Diana S. Aga ed., CRC Press 2008); Michael S.
Colucci, Henry Bork, & Edward Topp, Persistence of Estrogenic Hormones in Agricultural Soils: I. 17ß-Estradiol and Estrone, 30 Journal
of Environmental Quality 2070 (2001)).
306

Id.

307

With regard to temperature, Kinney et al., have noted seasonal variability:
Down-core migration of pharmaceuticals may occur from either the reclaimed-water irrigation or from pharmaceutical-free
precipitation. This result also could be explained by variations in the concentration of these compounds in the reclaimed water
or a change in removal/degradation rate. The latter could be accounted for by differences in soil microbial population dynamics.
Higher soil temperatures, consistent soil moisture, and perhaps, a steady supply of substrate and nutrients in the reclaimed water
could result in greater degradation of the compounds by soil microbes during the summer irrigation period compared to that during

the winter months.
Kinney et al. supra note 26, at 322 (emphasis added). Lozano, et al., noting that soil concentrations of triclosan (TCS) were quite
variable, concluded: “Our data suggests that the two most important parameters controlling TCS top soil concentrations are the biosolids
application rate and the time between application and sampling.” Lozano et al., supra note 90, at 762. This variability was also addressed in
Monteiro & Boxall, supra note 53, at 2546:
• “Laboratory studies show that degradation rates of pharmaceutical compounds in soils vary widely, with half-lives ranging from
days to years.” Id. (citing Alistair B.A. Boxall, Fate and Transport of Veterinary Medicines in the Soil Environment, in Fate of
Pharmaceuticals in the Environment an in Water Treatment Systems 123 (Diana S. Aga ed., CRC Press 2008)).
• “Within the same therapeutic class, half-lives can still be significantly different [20].” Id.(citing Michael P. Schlüsener & Kai
Bester, Persistence of Antibiotics Such as Macrolides, Tiamulin and Salinomycin in Soil, 143 Environmental Pollution 565
(2006)).
• “These differences are probably explained by differences in soil properties such as moisture content, organic carbon, pH, and soil
bioactivity; climate (temperature); and physicochemical properties of the compound such as degree of dissociation and
40

This variability, especially when considered over a national
scale, points to the difficulty of controlling or managing PPCPs
once they have been introduced into the environment.308 Different
PPCPs degrade at different rates and under different conditions
at different locations. Given the complexity of the problem, it is
highly likely that post-release solutions will be inadequate.

statute-specific strengths and weaknesses are discussed below,
many of the benefits and costs of a statutory or regulatory approach
are not statute specific.
Any regulatory program must be authorized by statute. Such
enabling legislation defines the scope of an agency’s regulatory
authority. Existing environmental statutes have vested substantial
authority in the Environmental Protection Agency (EPA). Similar
legislation at the state, territorial and tribal levels has vested
authority in entities whose functions mirror those of the EPA.309

Consequently, as discussed in greater detail below, eliminating
or reducing PPCPs in the waste stream is much more likely to
reduce both human and environmental risks than any postrelease
alternatives. In essence, it is much easier to keep PPCPs out of
waste stream than to safely dispose of waste containing PPCPs.

The result has been the development of substantial agency
expertise regarding specific issues. This is one of the major
strengths of the existing statutory/regulatory approach to
environmental regulation.

F. Strengths and Weaknesses of the
Statutory, Regulatory and Alternative
Strategies:

Agency expertise has developed as environmental law in
the United States has matured. At this point in the history of
environmental law, the requirements of the statutes are fairly well
known and understood, and the scope of EPA authority has been
established. The result is a fairly complete understanding of the
requirements of different statutes and regulations. As with the

F.1. Statutory and Regulatory
Statutory and regulatory approaches to the control of PPCPs
may have both substantial benefits and significant costs. Though

lipophilicity.” Id. (citing Edward Topp et al., Fate of the Nonsteroidal Anti-inflammatory Drug Naproxen in Agricultural
Soil Receiving Liquid Municipal Biosolids, 27 Environmental Toxicology and Chemistry 2005 (2008); Melanie Kah et
al., Factors Influencing Degradation of Pesticides in Soils, 55 Journal of Agriculture and Food Chemistry 4487 (2007);
Edward Topp et al., Biodegradation of Caffeine in Agricultural Soils, 86 Canadian Journal of Soil Science 533 (2006); and
M.S. Collucci et al., Persistence of Estrogenic Hormones in Agricultural Soils (I. 17-beta Estradiol and Estrone), 30 Journal of
Environmental Quality 2070 (2001)).
Such variability is not confined to the case study. A study of PPCPs in the Ann Arbor, Michigan water use cycle identified a number
of antibiotics, analgesics, antiepileptics, steroids and hormones in raw wastewater influent over a number of months. Variability in the
presence of these substances can be seen by comparing the mean concentrations with the standard deviation (a measure of variance):
308

Mean concentration
(µg/l)

Standard deviation
(µg/l)

Coprostanol (steroid/hormone)
Cholesterol (steroid/hormone)
Sitosterol (steroid/hormone)
Dihydrocholesterol (steroid/hormone)

682.500
560.000
241.500
67.500

568.880
451.368
173.077
46.458

Acetaminophen (analgesic)

53.000

37.151

Analyte

Stigmasterol (steroid/hormone)

37.125

Ibuprofen (analgesic)

11.000

27.497
7.685

Skadsen et al., supra note 77 at 4, Table 4.
309

The Food and Drug Administration also has substantial authority under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301

et seq. This authority, which includes the responsibility to ensure the safety and efficacy of both human and animal drugs (21 U.S.C. §
355), was expanded with enactment of the Food Quality Protection Act of 1996. The 1996 amendments authorized the Environmental
Protection Agency “to screen substances that may be found in sources of drinking water for endocrine disruption potential.” Keith A.
41

development of agency expertise, this is also one of the strengths of
the current statutory/regulatory system.

Likewise, any remedy provided by the court is limited to the
parties before the court. The outcome of litigation is influenced
frequently by the resources available to the parties. Any potential
outcome may change dramatically if the parties, for whatever
reason, choose to settle the litigation.

However, a weakness associated with this system is the limited
ability of the system to respond to site-specific issues. If PPCPs are
determined to be a threat to human health and the environment, for
example, a national regulatory program could be implemented based
on one of the statutes discussed herein. Unfortunately, the problem
of PPCPs may be localized as the number of variables identified in
the Section V case study would appear to indicate. The response
could be the proverbial use of a sledgehammer to kill a gnat.

In general, litigation has not proven to be an effective means of
protecting public health and the environment. That said, litigation
will certainly continue based both on common law tort theories
and the statutes discussed in Section III.
It is at least theoretically possible that a trespass action could
be brought involving PPCPs. In the Section V case study, for
example, treated effluent containing PPCPs was applied to lands
using center pivot irrigation systems. The researchers noted that
PPCPs were also found in soil samples taken from lands adjacent
to the areas where the treated effluent had been sprayed. It was
speculated that PPCPs were found on adjacent lands because of
run-off from the irrigated areas. On these facts, a trespass action
might be feasible. However, in order to recover more than merely
nominal damages, the plaintiff would have to prove that the
conduct of the defendant resulted in damage to the plaintiff. Given
the low levels of PPCPs noted in the case study, fulfilling the
burden of proof regarding damages may be difficult.

F.1.1. Common Law Remedies Sounding in Tort
Entitlement to relief under the common law remedies is based
on success in litigation. Since the common law tort theories
apply to disputes between individuals (civil wrongs as opposed to
criminal or societal wrongs), application of the theories arises in
the context of litigation between such individuals.
Consequently, all of the weaknesses of litigation as a means
of environmental regulation would be applicable to litigation
involving potential PPCP liability. Litigation is expensive and
time-consuming. Assuming that the party bringing the action has
the requisite legal standing, the scope of issues before the court is
limited to the issues raised by the parties which are almost always
unique to a specific case.

A public nuisance action might be possible if it could be
shown that the use of public “streams, parks, beaches and other

Johnston & Kristine Sendek-Smith, Muddy Waters: Recent Developments Under the Clean Water Act, 24-Winter Natural Resources
and Environment 31, 37 (2010):
Through what has been a long and contentious process, the EPA’s Endocrine Disruptor Screening Program is finally making
progress in helping identify endocrine disruptors from the tens of thousands of chemicals currently in use, and it will eventually
study the effects of those chemicals and compounds on humans and wildlife. EPA is near publication of the results of its sampling
performed in 2007 to determine the prevalenceof certain chemicals in drinking water and is also set to expand sampling this year
to obtain water samples from up to fifty drinking water treatment plants to help analyze the prevalence of about 200 emerging
contaminants in drinking water.

Id. at 37-38 (citing Alan Kovski, Drinking Water: EPA Details Emerging Contaminants Survey, Responds to Questions about Its Usefulness,
40 Environment Reporter 2361 (Oct. 9, 2009)). Johnston and Sendek-Smith also note that the U.S. Geological Survey is in the process
of developing a national reconnaissance program for emerging contaminants. This program is to focus “on four groups of compounds:
veterinary and human antibiotics, human drugs, industrial and household products (such as insecticides, detergents, fire retardants,
and fuels), and sex and steroidal hormones.” Id. at 38 (citation omitted). Authority for such a program, they note, is provided by the
Safe Drinking Water Act (42 U.S.C. § 300j-17), the Toxic Substances Control Act (15 U.S.C. § 2603), the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. §§ 346(a)(p), 408(p)) and the Federal Insecticide, Fungicide and Rodenticide Act (7 U.S.C. § 136(c)(2)(B)).
Id. In addition, Nidel has noted that the authority of the Food and Drug Administration “was expanded into the environmental realm by
enactment of the National Environmental Policy Act (NEPA), which not only provides FDA with the authority to bring environmental
considerations into its decisionmaking, but also requires that it take these considerations into account.” Christopher T. Nidel, Regulating
the Fate of Pharmaceutical Drugs: A New Prescription for the Environment, 58 Food & Drug Law Journal 81, 92 (2003) (citing 42
U.S.C.S. §§ 4321 et seq.). Accord Christenson, supra note 172, at 156; George J. Mannina, Jr., Medicines and the Environment: Legal and
Regulatory Storms Ahead?, 21 Legal Backgrounder, no. 11, 1, 3 (March 26, 2006).
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However, as noted above, litigation is always fact-specific. Given
an appropriate set of circumstances, application of one of the common
law tort theories might be an appropriate response to human and
environmental health injuries resulting from the release of PPCPs.313

facilities”310 was adversely affected by water supplies contained
PPCPs. Again, it would be the plaintiff ’s burden to show harm. As
noted above, given the low levels of PPCPs noted in the case study,
fulfilling this burden of proof requirement may be difficult.
Application of the theory of negligence might be appropriate
when it could be documented that a specific plaintiff was injured
by PPCPs released into the environment by a specific defendant.
However, this assumes that the appropriate chain of causation
could be established. This is not a safe assumption given the
ubiquitous nature of PPCPs. There is no question that the
manufacturers of PPCPs owe a duty of due care to prevent adverse
public and environmental health impacts. The weakness in trying
to apply the theory of negligence to such manufacturers is the great
degree of difficulty in determining the manufacturer of any specific
PPCP alleged to have caused harm.

F.1.2. The Clean Water Act
As noted in Section III, states are authorized to promulgate
water quality standards based on the National Recommended
Water Quality Criteria (“Criteria”). The state standards are then
subject to EPA approval. Lopez has argued that the Environmental
Protection Agency has a mandatory duty to revise the Criteria
“to establish limitations for EDCs [and other PPCPs] to protect
against endocrine disruption.”314 Should this occur, National
Pollutant Discharge Elimination System (NPDES) permits
ultimately would have to include appropriate measures to eliminate
or control PPCPs. Absent such an NPDES permit, discharges of
PPCPs from point sources into “waters of the United States” would
be prohibited.

Applying the theory of strict liability would be predicated
on the averment that PPCPs are inherently dangerous products
for which the manufacturers should be strictly liable. Given the
“value of the activity to the community”311 (i.e., the prevention
or treatment of disease), it would be exceptionally difficult, if not
impossible, for a plaintiff to demonstrate that PPCPs are inherently
dangerous.312

The wastewater treatment industry is familiar with both the
Clean Water Act and the use of NPDES permits. While this may
be one of the strengths of this approach to the control of PPCPs in

310

Restatement (Second) of Torts, supra note 96, at § 821D and related text.

311

Id. at § 402A.

For example, acetylsalicylic acid is used for both human therapy and in animal husbandry. It is “a nonsteroidal anti-inflammatory” that
is “also used for its analgesic, antipyretic and anti-coagulating properties.” Acetylsalicylic acid “is known to cause skin, eye and upper
respiratory tract irritation upon direct contact and gastrointestinal bleeding following chronic ingestion.” It is “a known systemic allergen
and can produce anaphylaxis at doses in the lowest end of the therapeutic range (10 mg/kg).” However, there is “strong epidemiological
evidence” that acetylsalicylic acid may also afford protection from some cancers. When used for both human therapy and in animal
husbandry, salicylic acid and other metabolites are excreted in urine and may end up in water supplies. On these facts, it would be difficult
to argue that acetylsalicylic acid is an inherently dangerous product, especially since its commonly used name is aspirin. Schulman et al.,
supra note 13, at 660 (citation omitted).
312

313

In fact, Mannina provides an example of such circumstances:
[A]n Illinois municipal water district which owns and operates a plant providing water to municipal residents and businesses
has sued the manufacturers of certain herbicides demanding that the manufacturers clean up all residue from a substance which
has found its way into the source of the drinking water and also pay for the costs of installing and operating additional water
treatment systems to guarantee the removal of any residue from this herbicide. What makes this case significant is that the
plaintiff does not allege the herbicide is being used unlawfully or contrary to the manufacturer’s instructions. Nor are there any
allegations of a violation of the safe drinking water standards established by EPA or the State of Illinois. Rather, the plaintiff,
citing various studies allegedly demonstrating adverse human health impacts of herbicide residue at concentrations less than
the existing safe drinking water standards, asserts that the federal and state standards are not protective of human health. The
plaintiff then asserts that the herbicide manufacturers are guilty under state law of trespass, nuisance, negligence, and releasing
“contaminants” into the environment solely because residue from the herbicide has come to be located in water owned and used by
the plaintiff. While this case does not involve pharmaceuticals or personal care products, one can imagine creative attorneys using
similar and related theories.

Mannina, supra note 309, at 3 (emphasis added).
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water supplies, it is also one of the weaknesses. If PPCPs are to be
controlled through the use of NPDES permits, which PPCPs should
the regulation target and using what technology? The plethora of
PPCPs would appear to require a plethora of control technologies.

publically-owned treatment works may be both financially and
politically impossible. As Jones has noted: “Although the public
may want pure water, people are not prepared to pay what it would
actually cost even if sufficient technology did exist.”321

A directly related question, assuming that control of PPCPs
is mandated at wastewater treatment plants, focuses on treatment
techniques and systems. As noted in Section IV, new water
treatment systems have been (and are being) developed.315 A
number of authors have noted the need for these technological
developments to continue. Nidel, for example, notes the
need to development new wastewater treatment systems that
“more effectively break down these compounds leaving only
environmentally inert effluents.”316 The related question, therefore,
is whether the development and use of new wastewater treatment
technology should be a condition precedent to the issuance of
NPDES permits.

Finally, perhaps the most significant limitation regarding use
of the Clean Water Act as a means of preventing the introduction
of PPCPs into water supplies is the fact that the statutory
requirements do not apply to nonpoint sources of wastes. Such
nonpoint sources (e.g., runoff from farms) are “a significant sources
of the pharmaceuticals found in surface water[.]”322

F.1.3. The Safe Drinking Water Act
Inclusion of PPCPs in the National Primary Drinking Water
Regulations would be one means of limiting human exposure to PPCPs.
Maximum Contaminant Level Goals (MCLGs) and Maximum
Contaminant Levels (MCLs) could be established for PPCPs.

Requiring pretreatment of wastes containing PPCPs has been
suggested.317 Such requirements would be applicable to a variety
of entities (i.e., manufacturing facilities, health care facilities) that
discharge wastes containing PPCPs.318 The goal of such requirements
would be to mandate the pretreatment of wastes that would either
interfere with the operation of a wastewater treatment plant or that
would pass through a wastewater treatment plant untreated.319

In fact, such an approach is being considered by EPA. As
indicated in Section III, the Contaminant Candidate List (CCL)
includes contaminants not presently subject to the National
Primary Drinking Water Regulations but which may have an
adverse impact on human health and is known to occur in water
supply systems. If so, the EPA Administrator may subject the
contaminant to the National Primary Drinking Water Regulations.
The current CCL, which was published on 21 August 2008, lists
104 contaminants.323 Unfortunately, virtually all of the PPCPs that

Assuming that wastewater treatment techniques and systems
can be developed to control the plethora of PPCPs, the cost
could be staggering.320 Imposing such costs on the operators of

Jacki Lopez, Endocrine-Disrupting Chemical Pollution: Why the EPA Should Regulate These Chemicals Under the Clean Water Act,
Spring Sustainable Development Law and Policy 19, 22 (2010).
314

315

Supra, notes 268 to 280 and associated text.

Nidel, supra note 309, at 82. However, “this solution is under-inclusive [in that it] does not address the large amounts of animal drugs
that make their way directly into the environment.” Id. at 91.

316

Christenson, supra note 172, at 163 (citing P.G. Kent & T.A. Dudiak, WISCONSIN WATER LAW: A GUIDE TO WATER
RIGHTS AND REGULATIONS 104 (2d ed. 2001)).
317

318

Id.

319

Id.

“The total costs of removing every possible endocrine disrupting compound could quickly become astronomical.” Jones, supra note 229,
at 385-386.

320

321

Id. at 386.

Christenson, supra note 172, at 148 (citing P.G. Kent & T.A. Dudiak, Wisconsin Water Law: A Guide to Water Rights and
Regulations 107 (2d ed. 2001)).

322

323

Notice, Drinking Water Contaminant Candidate List 3, 73 Fed. Reg. 9628 (2008).
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or the general environment. The current CCL process for
chemicals would not identify this as an adverse effect.325

were proposed for inclusion on the CCL were not included.324
Perhaps because of this outcome, the Science Advisory Board
Drinking Water Committee of the EPA Office of Ground Water
and Drinking Water recommended changes to the CCL selection
process:

A final decision regarding “whether to regulate five of more
of the contaminants from this list” is expected by 2013.326 If
PPCPs are included within the regulatory scope of the Safe
Drinking Water Act, it has been suggested that a “No Observed
Transcriptional Effect Level” (NOTEL, defined as “the dose
of chemical which results in no significant changes to gene
expression”) should be the regulatory limit.327

The Committee recommends consideration of emerging
issues and on-going research when selecting chemicals.
There are also some clear categories of contaminants that
need special attention in selecting the CCL including
pharmaceuticals, personal care products, endocrine
disruptors, antibiotics, and algal toxins. Such contaminants
may warrant changes in the CCL selection processes.
General exposure to even low levels of antibiotics in
drinking water, for example, may lead to antibioticresistant pathogens either in a person drinking the water

324

The weakness of this approach has been noted already: the
ubiquitous nature of PPCPs. As with alternatives under the Clean
Water Act, requiring public water supply systems to address all
PPCPs could impose financial burdens that are neither financially
nor politically feasible.

The process that preceded the current Contaminant List was described by ToxServices LLC:
EPA identified 287 pharmaceuticals in its initial listing of a broad range of potential drinking water contaminants in the draft
CCL3 [Drinking Water Contaminant Candidate List 3] that had data to indicate a potential to occur in drinking water and
health effects. The health data used was primarily from the FDA’s Database on Maximum Recommended Daily Doses and
the occurrence data was from the U.S. Geological Survey’s Toxic Substances Hydrology Program’s National Reconnaissance
of Emerging Contaminants, and TRI [Toxic Release Inventory] and high production volume chemical data. Further screening
moved approximately 10 percent of the pharmaceuticals to the preliminary CCL. Only one of the pharmaceuticals, nitroglycerin,
was included in the draft CCL3.

ToxServices LLC, supra note 34, at 12.
EPA Science Advisory Board Drinking Water Committee, Environmental Protection Agency, Sab Advisory on EPA’s Draft
Third Drinking Water Contamination Candidate List (CCL 3) 7 (2009). The Committee also addressed PPCPs in the context
of contaminants that were not included on the draft CLL. With regard to concentrations of contaminants in wastewater and the potential
reuse of such water supplies, the Committee concluded:
325

The Committee concludes that it will be important to consider information regarding wastewater concentrations when evaluating
potential exposure in the CCL process. In some areas of the country, wastewater discharges are increasingly a greater percentage
of water supplies, and they are being processed into potable water. Wastewater contains a wide variety of contaminants including
pharmaceuticals, personal care products, enteric pathogens, and other emerging contaminants. In the case of pharmaceuticals,
perflourinated surfactants, and other contaminants that are prevalent in wastewater effluent, EPA may want to consider using data
obtained in specialized wastewater effluent monitoring programs for the CCL screening process.

Id. at 14. In terms of chemical contaminants, the Committee noted the absence of data:
The absence of data on the occurrence of pharmaceuticals in surface waters was also noted. The Committee recommends use of
the data from the USGS, or any of the numerous studies in the peer-reviewed literature, to include these chemicals.

Id.
Johnston & Sendek-Smith, supra note 309, at 38 (citing Alan Kovski, Drinking Water: EPA Completes List of Water Contaminants to
Consider as Candidates for Regulation, 40 Environment Reporter 2246 (Sept. 25, 2009)). EPA has also considered inclusion of PPCPs
326

within the Unregulated Contaminant Monitoring Rule.
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F.1.4. The Resource Conservation and Recovery Act

The Surface Water Treatment Rule could be amended to
require removal of PPCPs in addition to the contaminants already
subject to the Rule. Again, the cost of such an approach may not
make it financially or politically opportune.

The definition of a “hazardous” waste contained in the
Resource Conservation and Recovery Act (RCRA) could be
expanded to include additional wastes containing PPCPs.328 At
the present time, for example, wastes discharged pursuant to a
National Pollutant Discharge Elimination System Permit are not
subject to the requirements of RCRA.

An alternative that may not face the twin roadblocks of
financial and political feasibility would be to amend the Wellhead
Protection Program to preclude the discharge of wastes containing
PPCPs in wellhead protection areas. For example, prohibiting
either (a) the installation or use of septic tanks in wellhead
protection areas or (b) the land application of wastewater treatment
plant residues (biosolids) in such areas could protect groundwater
from wastes containing PPCPs.

Inclusion of wastes containing PPCPs within the definition
of a “hazardous” waste would subject the waste stream to the
requirements of RCRA.329 Generators and transporters of wastes
containing PPCPs, as well as operators of treatment, storage and
disposal facilities (TSDF) for such wastes, would have to comply
with the requirements of RCRA, including use of the Uniform
Hazardous Waste Manifest System and permit requirements to
construct and operate a TSDF.

A similar amendment could be implemented regarding the
Underground Injection Control Program. Injection of wastes
containing PPCPs could be restricted to Class I injection wells.
As with the possible amendment to the Wellhead Protection
Program, the goal would be to prevent the migration of PPCPs
into groundwater resources.

However, because of the limited number of TSDFs and the
difficulty of establishing new TSDFs, imposing such requirements
could be both costly and burdensome to the waste management
community. The volume of waste subject to RCRA requirements
would increase dramatically. The cost of disposing such waste
could increase in proportion to the quantity of wastes generated.

Sludge or biosolids containing PPCPs from water treatment
plants could be subject to the Part 503 Biosolids Rule. The Rule
would have to be amended to establish both ceiling and loading rate
limits for PPCPs. As noted in the case study, liquid wastes containing
PPCPs were used to irrigate a waste disposal site. It may be necessary
to expand the Biosolids Rule to apply to such situations.

One result seen repeatedly when disposal costs are excessive
is an increase in illegal dumping of hazardous wastes. If costs
increase because of an imposition of RCRA requirements on wastes
containing PPCPs, the resultant illegal dumping would most likely
include a wide variety of hazardous wastes that previously would
have gone to an approved TSDF.

Poynton & Vulpe, supra note 34, at 91 (citing E.K. Lobenhofer et al., Exploration of Low-Dose Estrogen Effects: Identification
of No Observed Transcriptional MAQC Effect Level (NOTEL), 32 Toxicologic Pathology 482 (2004); Gerald T. Ankley et al.,
Toxicogenomics in Regulatory Ecotoxicology, 40 Environmental Science & Technology 4055 (2006)). As Poynton and Vulpe concluded,
327

“[a]ny significant cellular perturbation should cause some change in gene expression; therefore, the NOTEL represents a true No
Observed Effect Concentration.” Id. at 91.
328

Christenson addressed this approach in the context of health-care facilities, concluding:
[T]he list of hazardous drugs “has not been substantially updated since the rules went into effect in 1976.” For example, only
eight out of 100 different chemotherapy drugs are currently on the list of hazardous wastes. In fact, health-care facilities have an
extremely difficult time dealing with the RCRA because the regulations were not designed for the health-care industry. Thus,
when there are regulations, they are complicated and expensive to follow, and when there are not regulations, hospitals are left in
the unenviable position of developing their own disposal programs or flushing drugs down the toilet.

Christenson, supra note 172, at 150 (citing R. Seely, Flushed Drugs Polluting Water; Complicated Rules for Disposal Result in Most
Hospitals Taking Easy Way Out, Wisconsin State Journal, Dec. 10, 2006, at A1.). See also, Mannina, supra note 309, at 4 (“Provisions
in RCRA and in Drug Enforcement Administration regulations which are designed to protect the public from the improper discharge or
disposal of medical waste and controlled substances may, in reality, be encouraging medical professionals and the public to flush unused
pharmaceuticals in toilets or drains.”).
329

As noted by Mannina:
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However, concerns have been expressed regarding the inclusion
of PPCPs on the Universal Waste list. These concerns focus on
the contention that the regulation of PPCPs under the Universal
Waste Rule “may be less stringent than the rules for hazardous
wastes under RCRA.”336

An alternative could be to revise the Universal Waste Rule to
include PPCPs. In fact, on December 2, 2008, the EPA proposed
adding PPCPs to the Universal Waste list.330 The proposed
revisions would add hazardous pharmaceuticals to the list. The
rule, as amended, would apply to pharmacies, hospitals, physicians’
offices, dentists’ offices, outpatient care centers, ambulatory health
care services, residential care facilities and veterinary clinics as well
as other facilities that produce hazardous pharmaceutical wastes.331
EPA has estimated that the proposed revision would affect up to
634,552 entities, of which approximately 181 are large quantity
generators of hazardous waste.332 The amendments would allow
producers of hazardous pharmaceutical wastes to choose whether
(a) to continue to have their wastes regulated under the current
RCRA regulations or (b) to manage their hazardous wastes under
the Universal Waste Rule.333

F.1.5. The Toxic Substance Control Act
Solid and liquid wastes containing PPCPs could also be subject
to the requirements of the Toxic Substances Control Act (TSCA).
If so, Title I of TSCA would require manufacturers and processors
of such wastes to conduct a testing program “to predict the effects
of human exposure and environmental releases.”337
Regulatory controls are available under TSCA regarding the
processing, distribution, use or disposal of a chemical presenting
an unreasonable risk of injury to health or the environment.338 If
wastes containing PPCPs fall within the purview of TSCA, then
this provision, as well as all of the regulatory controls authorized by
TSCA, could be applicable. If so, given the wide variety of PPCPs,
the potential scope and cost of complying with these requirements
could make compliance problematic.

The proposed revision is also intended to facilitate the
collection of pharmaceutical wastes from households, including
non-hazardous pharmaceutical wastes.334 Of relevance to the
source control options discussed below, EPA believes that the
amendments will simplify pharmaceutical take-back programs
by “streamlining the requirements for handling hazardous
pharmaceutical wastes received as part of a take-back program.”335

EPA has listed several common medications and nine chemotherapy agents as hazardous waste if discarded. But there are more
than 100 toxic chemotherapy agents which are not yet RCRA regulated.
Mannina, surpa note 309, at 2. Regulation of these wastes could have unintended consequences:
If regulated substances are released into the environment, as those terms are understood under Superfund [the Comprehensive
Environmental Response, Compensation and Liability Act, 42 U.S.C. § 9601 et seq.] and the Clean Water Act, can we look
forward to cleanup orders and claims for natural resource damages under those laws? The answer is probably yes.

Id.
Amendment to the Universal Waste Rule: Addition of Pharmaceuticals, 73 Fed. Reg. 73520 (Dec. 2, 2008) (to be codified at 40 C.F.R.
pt. 260, 261, 264, 265, 268, 270 and 273).
330

331

Environmental Protection Agency, EPA Proposes Streamlined Disposal of Hazardous Pharmaceutical Waste (Nov. 2008),

available at http://www.epa.gov/osw/hazard/wastetypes/universal/pharm-fs.pdf.
332

Amendment to the Universal Waste Rule: Addition of Pharmaceuticals, 73 Fed. Reg. at 73520.

333

Id.

334

Id.

335

Id. at 73526.

Johnston & Sendek-Smith, supra note 309, at 38 (citing Environmental News Stand, EPA Urged to Up RCRA Pharmaceuticals
Enforcement at Hospitals, INSIDE EPA (July 1, 2009).
336

337

TSCA, § 2603, supra note 196 and associated text.

338

Id. at § 2605(a).
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F.1.6. The Endangered Species Act

case, a federal judge upheld a finding that fishing was
adversely affecting an ESA-protected species even though
there was no evidence that fishing was causing any impact.
The logic, using the ESA’s insure no harm standard, was
that fishermen catch fish, the listed species eat fish, and,
therefore, there must be an adverse impact from fishing.

The financial and political burdens confronting use of the
aforementioned statutes would cease to be a threshold issue if
wastes containing PPCPs led to the “taking” of a threatened or
endangered species. As discussed in Section II, the impacts of
PPCPs in water supplies have been observed in a wide variety
of aquatic species. At some point, a cause of action will arise
when PPCPs in water supplies result in the “taking” of a species
protected by the ESA or similar legislation enacted by state, local
or Tribal governments.339

Apply that reasoning to pharmaceuticals in the environment
and it is not a very long leap before the ESA can be brought
to bear on protected species such as the razorback sucker and
other listed species of fish, including virtually all the salmon
and steelhead species in the Pacific northwest.343

In fact, these causes of action may already have ripened.
Lopez notes that “[t]here is evidence that EDCs are significantly
degrading habitat, including federally designated critical habitat,
and are likely injuring fish and wildlife by disrupting behavior
patterns such as breeding ability.”340 This could give rise to a
“taking” cause of action regarding a number of threatened or
endangered species including the Razorback Sucker (Xyrauchen
texanus), the Desert Pupfish (Cyprinodon macularius) and the
Santa Ana Sucker (Catostomus santaanae).341

Implementing a recovery plan under the ESA can be both
socially disruptive and expensive. The preferred alternative is to
take whatever steps might be needed to preclude the need to list a
species as threatened or endangered. This could include regulating
or prohibiting the discharge of wastes containing PPCPs,
especially if the cause of the “taking” is related to the discharge
of such wastes. While such an approach may not be politically
popular, the alternatives (listing a species and implementing a
recovery plan) are substantially less popular.

An alternative cause of action noted by Mannina is based on
the ESA requirement that “federal agencies (including agencies
approving the use of pharmaceuticals and hormones) ‘insure’ that
any action they take or authorize is not likely to adversely affect
species protected by the ESA.342 Based on this requirement,
Mannina concluded:

F.2. Alternative Strategies
The source control alternative strategies discussed in Section IV
may be more effective in reducing or eliminating PPCPs in water
supplies than the imposition of a statutory or regulatory approach.
The approaches advocated by Daughton and others focus on
minimizing or eliminating sources of PPCPs.344

Experienced ESA attorneys are all too well aware of how
little proof of impact is required before the ESA’s “insure”
no harm standard triggers regulatory controls. In one ESA

The Endangered Species Act is not the only federal species protection statute that might provide a cause of action should protected
species be affected adversely by PPCPs. See, e.g., the Bald and Golden Eagle Protection Act, 16 U.S.C. §§ 668-668d; the Marine Mammal
Protection Act, 16 U.S.C. §§ 1361- 1421h; the Migratory Bird Treaty Act, 16 U.S.C. §§703-712. Similar species protection legislation
enacted by state, local and Tribal governments might provide additional causes of action.
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Lopez, supra note 314, at 20 (citing Susan Jobling et al., Wild Intersex Roach (Rutilus rutilus) Have Reduced Fertility, 67 Biology of
Reproduction 515 (2002) (finding that EDC-caused altering of sex characteristics leads to reduced reproductive ability)).

340

Id. at 21. See also, Mannina, supra note 309, at 2 (“ESA issues may already be present in Nevada where a USGS toxicologist detected
elevated levels of pharmaceuticals and hormones in waterways downstream from Las Vegas and a very large decrease in sperm production
in three species of fish, including the endangered razorback sucker.”).
341

342

Mannina, supra note 309, at 2.

343

Id. (emphasis added).

As in Section IV, the discussion in this Section focuses primarily on pharmaceuticals. Nevertheless, the analysis is equally applicable to
personal care products and the full array of PPCPs previously identified in footnote 6. See supra note 4.
344
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F.2.1. Drug Design

F.2.2. Drug Delivery

Designing drugs to minimize the human and animal
excretion of wastes containing PPCPs would have the effect of
reducing the volume of PPCPs entering water supplies. Any
number of commentators have argued that the Food and Drug
Administration (FDA) needs to assess the PPCP discharge
potential as a component of the FDA’s drug approval process. 345
Such an assessment could be undertaken in the context of the
Environmental Assessment process mandated by the National
Environmental Policy Act.346 “The hope,” observed Nidel, “is
that with an adequately informed FDA sitting as gatekeeper to
this highly profitable market, drug design will evolve. This will
lead drug companies to internalize the external impacts of their
products and, where feasible, design drugs of the future that are
noted for their minimal impact on the environment as well as for
their therapeutic effectiveness.”347

The drug delivery alternatives suggested by Daughton are
predicated in part on voluntary participation by physicians, patients,
pharmacies and drug manufacturers. Despite Daughton’s faith in
public education programs, such appeals to conscience have not been
an effective means of addressing environmental health problems. 350

F.2.3. Drug Marketing
The cost of informing consumers of appropriate means of
discarding unused drugs should be minimal vis-à-vis the benefit of
reducing PPCPs in water supplies. However, the cost of producing
a variety of package sizes in order to minimize the quantity of
unused drugs needing disposal could be substantial. Given the
sensitivity of consumers to drug prices, those alternatives with the
least costs are more than likely the most feasible.

As noted below,348 Daughton has suggested that patent
extension be used as an incentive to encourage drug companies
to implement alternative source control strategies. Others have
suggested the need for financial incentives or other types of
financial support, particularly with regard to drug design.349

F.2.4. Drug Dispensing
McGrath notes that the State of Maine has limited the quantity
of drugs that physicians may “prescribe for first-time users of
certain medications.”351 The political feasibility of such an approach
raises issues regarding both the social responsibility of physicians
and the role of the state in the doctor-patient relationship.

Despite the provision of such financial support, a restraint
on the feasibility of this alternative could be the need for drug
manufacturers to pass the cost of drug development to the
general public. Absent a definitive showing of adverse human or
environmental health impacts resulting from exposure to PPCPs,
the political feasibility of increasing the cost of drugs in order to
limit PPCPs in water supplies is an open question.

Dispensing the correct quantity of a drug with an appropriate
expiration date (i.e., the drugs will not expire before the course
of treatment has been completed) could be a win-win situation,
at least for the patient and the environment. Whether such an
approach would be considered a “win” for drug manufacturers is an
open question.

As Nidel has noted, “[r]equring a more rigorous assessment when applying for new drug approval would shift the focus of the root-cause
of the problem.” Nidel, supra note 309, at 82.

345

346

Id. at 92-93.

347

Id. at 100.

348

Infra, note 360 and associated text.

Christenson, supra note 172, at 169 (citing Nidel, supra note 309, at 94 for the proposition that the Food and Drug Administration
“already has the necessary authority” to “increase environmental review of the design of new drugs or offer intellectual-property or taxbased incentives to those manufacturers who voluntarily test for environmental effects.”).

349

See, e.g., Garrett Hardin, The Tragedy of the Commons, 162 Science 1243, 1246-1247 (the “tragedy of the commons” cannot be
remedied by appeals to conscience).
350

Neal McGrath, Water Pollution: Pharma’s Next Big Headache?, Greenbiz.com Blogs (August 31, 2009),
http://www.greenbiz.com/blog/2009/08/28/water-pollution-pharmas-next-big-headache.
351

49

F.2.5. Drug Disposal/Recycling

impediment to takeback programs, that “the same pharmacist
who is authorized to distribute medications … is not authorized to
take the medication back without prior approval by a DEA [Drug
Enforcement Administration] agent.” 353

Existing institutional barriers to drug disposal and recycling
need to be revised. While there may be good reasons for some of
these barriers to continue (e.g., prevention of theft of discarded
pharmaceuticals), blanket prohibitions encourage the inappropriate
disposal of unused or unwanted drugs.

Despite such impediments, a number of states have sought to
develop drug take-back programs. For example, legislation enacted
in Maine authorized a drug mail-back program. 354 The program
was summarized by Christensen:

One approach to a drug disposal and recycling program would
be a “take-back” program such as the one described by Christensen:

Consumers mail unused or expired drugs in these
packages to a single collection location run by the Maine
Drug Enforcement Agency (MDEA). The MDEA then
disposes of all returned drugs in an environmentally
sound manner. A fund established and maintained by
the MDEA and funded by private contributions pays the
costs of the program. 355

Take-back events, typically organized by hospitals,
pharmacies, or environmental groups, create a place for
consumers to bring their unused pharmaceuticals. With
proper personnel available to sort pharmaceuticals and
law enforcement available to handle controlled substances,
these events are often extremely successful, resulting
in hundreds of gallons of pharmaceuticals collected in
single-day events. 352

Implementation of the Maine program encountered two
problems. First, “although manufacturers regularly package and ship
prescription drugs for consumption, it is much more difficult to have
them shipped for disposal.” 356 Second, “due to the potentially high
costs involved, it is unlikely that pharmaceutical companies would
provide the necessary funds to run the entire program.” 357

The successful implementation of drug take-back programs
has been challenging. As noted above, having “law enforcement
available to handle controlled substances” may be a condition
precedent to a successful program. This statement masks a serious

Christenson, supra note 172 at 157 (citing R. Seely, Flushed Drugs Polluting Water; Complicated Rules for Disposal Result in Most
Hospitals Taking Easy Way Out, Wisconsin State Journal, Dec. 10, 2006, at A1; R. Dickrell, Pharmaceutical Take-Back A Community’s
Success Story, 167 The Clarifier 48 (2006)).
352

353

Id. at 151 (citing Juliet Eilperin, Pharmaceuticals in Waterways Raise Concern: Effect on Wildlife, Humans Questioned, Washington

Post, June 23, 2005, at A3).
For the health-care industry and consumers, “DEA laws are one of the biggest stumbling blocks” on the road toward proper
disposal. This is largely due to the DEA’s strict control of controlled substances, under which disposal becomes quite complicated.
When an individual is unsure how to dispose of a controlled substance, that individual may contact an authorized DEA agent, who
will then instruct the individual to dispose of the controlled substance in one of the following manners: (1) by transfer to a person
authorized to possess controlled substances (likely a law-enforcement officer), (2) by delivery to a DEA agent, (3) by destruction in
the presence of a DEA agent, or (4) by some other means determined by a DEA agent. In other words, the only persons who can
possess a controlled substance that is prescribed to an individual are that individual, a law-enforcement officer, or a DEA agent.

Id. at 151-152 (citing R. Seely, Flushed Drugs Polluting Water; Complicated Rules for Disposal Result in Most Hospitals Taking Easy Way
Out, Wisconsin State Journal, Dec. 10, 2006, at A1; 21 C.F.R. § 1307.21 (Drug Enforcement Administration, Office of Diversion
Control, Procedure for disposing of controlled substances)).
As opposed to a take-back event as described above, a “statewide mail-back model offers a centralized coordination component, adds
an element of confidentiality and anonymity not found with in-person take back programs and is the least burdensome of all models
in terms of consumer access and utilization.” Lenard Kaye, Jennifer Crittenden, & Stevan Gressitt, Executive Summary: Reducing
Prescription Drug Misuse Through the Use of a Citizen Mail-Back Program in Maine (2010), available at http://www.epa.gov/
aging/RX-report-Exe-Sum/.
354

355

Christenson, supra note 172, at 154 (citing Me. Rev. Stat. Ann. tit. 22 §§ 2700(3)-(5)).

356

Id. (citing Me. Rev. Stat. Ann. tit. 22 § 2700(4)).

357

Id. at 155 (citing Juliet Eilperin, Pharmaceuticals in Waterways Raise Concern: Effect on Wildlife, Humans Questioned, Washington
50

McGrath notes that seven states have considered legislation
to “mandate take-back programs” and that a mandatory system,
funded by the drug companies, has been implemented in France.
358
Alternative programs would include the Canadian Medications
Return Program 35 Daughton’s suggestion to extend the patents
of drug companies implementing “vibrant, comprehensive
stewardship programs tailored for each particular drug” 360 has
merit, but it also could mean that consumers could pay higher drug
prices over time because the introduction of alternative generic
drugs could be delayed by the patent extensions. 361

G. Conclusions:
The words of H.L. Mencken ring true: “For every complex
problem, there is a solution that is simple, neat, and wrong.”
Mencken’s conclusion appears to be particularly appropriate
regarding PPCPs in water supplies.

F.2.6. Drug Alternatives

The general conclusions are deceptively simple: The
anthropogenic sources of PPCPs identified in Section II need to
be reduced or eliminated. As discussed in Section III, such sources
of PPCPs may be subject to regulation. As discussed in Section
IV, source control alternatives exist that could have the effect of
reducing or eliminating some sources of PPCPs without the costs
associated with statutory or regulatory programs.

The benefit of drug alternatives is a reduction in the discharge
of PPCPs associated with the use of such products. The burden
has been stated already: potential cost to the patient. The use of
“bacteriotherapy” may be as effective as the use of a drug resulting
in the discharge of PPCPs, but at what cost? Perhaps more
importantly, does the reduction in PPCPs discharged into water
supplies justify the cost?

The devil, however, is in the details. As noted by Wennmalm
and Gunnarsson, “The consumption of pharmaceuticals is
increasing worldwide, due both to continued population growth and
increased consumption of pharmaceuticals per capita.”362 The everincreasing number of PPCPs363 combined with the concentration
variability discussed in Section V precludes any single approach to

Post, June 23, 2005, at A3). Christenson notes the issue of political feasibility:
Maine’s government could consider legislation that would require pharmaceutical companies to significantly contribute to
the fund. However, given that the pharmaceutical industry is one of the leading lobbyists in the United States, any proposed
legislation that would force manufacturers to significantly contribute to the fund would likely meet significant opposition.

Id. (citing Jim Drinkard, Drugmakers Go Furthest to Sway Congress,” USA Today, Apr. 26, 2005, at B1 (drug companies spent more on
lobbying than any other industry from 1998 to 2004)).
358

McGrath, supra note 350.

359

Christenson, supra note 172, at 157-158 (citing Daughton, “Drug Disposal, Waste Reduction, and Future Directions,” supra note 232 at 780).

Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note 230, at 776. The concept of stewardship underlay the
Maine mail-back program. “Product stewardship is a concept that recognizes the responsibility of the manufacturer of a product from
the manufacturing process through final disposal in an environmentally sound manner.” State of Maine Final Report of the Maine Drug
Return Implementation Group, 122nd Legis., 1st Reg. Sess. at 7 (2005), available at http://www.maine.gov/legis/opla/drugrpt.pdf,
(quoted in Christenson, supra note 172, at 154).

360

As noted by Christenson, “[i]f the scheme places the financial burden on consumers, it fails to follow the product-stewardship model
that underlies this solution.” Christenson, supra note 172, at 155.
361

Wennmalm & Gunnarsson, supra note 41, at 291 (citing European Federation of Pharmaceutical Industries and Associations. The
Pharmaceutical Industry in Figures (2002)). Consumption of pharmaceuticals is increasing 3-4% by weight per year. Ellis, supra
note 30, at 185 (citing Christian G. Daughton, Non-regulated Water Contaminants: Emerging Research, 24 Environmental Impact
Assessment Review 711 (2004)). Accord Reynolds, Concern of Pharmaceuticals in Drinking Water, supra note 33, at 2.
362

“[T]here may be as many as 6 million PPCP substances commercially available worldwide[.]” Ellis, supra note 30, at 185 (citing Christian
G. Daughton, Non-regulated Water Contaminants: Emerging Research, 24 Environmental Impact Assessment Review 711 (2004)).

363
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process will be capable of reducing all trace organic contaminants to
below increasingly sensitive analytical detection limits.”371

their regulation or management.364 New monitoring,365 detection366
and analysis367 methods are needed. New management alternatives
need to be developed. New statutory or regulatory approaches
embodying the Precautionary Principle368 need to be tailored to the
goal of reducing PPCPs in water supplies.369

As noted in the Introduction, this report is predicated on
the assumption that the ongoing scientific inquiry regarding the
effects of PPCPs in water supplies produces evidence of risks to
human and environmental health. If so, then all of the alternatives
discussed herein, as well as any number of additional alternatives
that have yet to emerge, will be needed if both human and
environmental health are to be protected.

It is quite possible that new drinking water treatment processes
will need to be developed. However, while such processes might
protect human health, they would “provide no protection for aquatic
life.”370 Furthermore, it is unlikely that any “single water treatment

“The aging population and more pharmaceutical development are two driving factors behind an expectation that increased
pharmaceutical use will result in higher levels of trace residues in water.” Global Water Research Coalition, supra note 31, at 2. Accord
Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 25 (“a growing and aging population as well as increased reliance on
drug treatments, and development of new drugs, the problem with pharmaceutical contamination promises to also increase”).
364

G. Tracy Mehan, III, Water Data and Monitoring as Indispensable Tools to Manage Water Quality, Daily Environment Report,
August 4, 2010, at 4.

365

“Methods of detection are not available for all pharmaceuticals, and new pharmaceuticals are developed every year, which may require
new methodologies to enable their detection in water.” Global Water Research Coalition, supra note 31, at 1.
366

367

Poynton & Vulpe, supra note 34, at 92:
New chemicals and drugs are continuously developed and released in the environment. New approaches are needed for environmental
risk assessment to catch up with the backlog of contaminants and keep pace with the increasing surge of new potential risks.

Accord Rapid Public Health Policy Response Project. supra note 26, at 3-4 (need for human health assessments of low-level, chronic
exposure to PPCPs); Jones, supra note 231, at 385 (need for new risk assessment models that account for synergistic effects).
“Irrespective of any risks, the precautionary principle should apply and micropollutants from wastewater should not be present in
drinking water.” C. Zwiener, Occurrence and Analysis of Pharmaceuticals and their Transformation Products in Drinking Water Treatment,
387 Analytical and Bioanalytical Chemistry 1159 (2007) (quoted in Rapid Public Health Policy Response Project, supra note 26,
at 6. Among the various definitions of the Precautionary Principle, perhaps the one most applicable to PPCPs is the definition resulting
from the Wingspread Conference on the Precautionary Principle (26 January 1998): “When an activity raises threats of harm to human
health or the environment, precautionary measures should be taken even if some cause and effect relationships are not fully established
scientifically.” The conferees went on to explain that the “precautionary principle shifts the burden of proof, insisting that those responsible
for an activity must vouch for its harmlessness and be held responsible if damage occurs.” Science and Environmental Health Network,
http://www.sehn.org/wing.html (last visited Jan. 30, 2011).
368

See, e.g., Heberer et al., Removal of Pharmaceutical Residues, supra note 85, at 19 (citing T. Heberer & H.-J. Stan,
Arzneimittelrückstände im Aquatischen System, 50 Wasser und Boden 20 (1998); Umweltbundesamt, Annual Report 1999 (2000)):
369

[L]ow concentrations [of pharmaceutically active compounds] may, from a toxicological point of view, not be harmful to
humans but their occurrence in ground or drinking water is also not desirable from a hygienic point of view or with regard to the
precautionary principle. Thus, there is a need to develop and study new drinking water treatment technologies to remove such
organic contaminants from drinking water.

Accord Wennmalm & Gunnarsson, supra note 41, at 296 (“in line with the precautionary principle, measures should be taken by public
health authorities to avoid contamination of drinking water with … low concentrations of bioactive chemicals such as pharmaceuticals”).
370

Snyder et al., supra note 47, at 34.

Stanford et al., supra note 11, at 56 (citing Benotti et al., supra note 48; Shane A. Snyder et al., American Water Works Association,
Removal of EDCs and Pharmaceuticals in Drinking and Reuse Treatment Processes (2007) ; Brett J. Vanderford & Shane A. Snyder,
Analysis of Pharmaceuticals in Water by Isotope Dilution Liquid Chromatography/Tandem Mass Spectrometry, 40 environmental Science
& Technology 7312 (2006)).
371
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